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DISCOVERY OF NATURAL PRODUCT ANALOGS AGAINST ETHANOL-
INDUCED CYTOTOXICITY IN HIPPOCAMPAL SLICE CULTURES 
 
An estimated 13.9% of Americans currently meet criteria for an alcohol (ethanol; 
EtOH) use disorder (AUD). While there are 4 medications approved by the Food and 
Drug Administration (FDA) to treat AUD, these treatments have demonstrated poor 
clinical efficacy. Our ongoing research program encompasses a multi-tiered screening of 
a natural product library and validation process to provide novel information about the 
mechanisms underlying EtOH-induced changes in neurobiology and to identify novel 
chemical scaffolds to be exploited in the development of pharmacological treatments for 
AUD in a rodent organotypic hippocampal slice culture model. Initial screens of several 
natural product compounds identified 3 compounds which attenuate 48 h EtOH-induced 
cytotoxicity in vitro. As analogs of natural products can be developed to have enhanced 
therapeutic potential over parental structures, Study 1 sought to extend on prior findings 
via the screening of several natural product analogs for their ability to attenuate EtOH-
induced cytoxicity. Nine natural produce analogs demonstrated potent cytoprotective 
effects against EtOH-induced toxicity at 48 h. Several reports suggest EtOH-induced 
neurotoxicity may be secondary to the induction of persistent neuroimmune activation, 
and isoflavonoids have been shown to have effects on neuroimmune signaling. Thus, 
Study 2 compared the effects of compound 9b, an isoflavonoid analog identified in Study 
1, to daidzein (DZ), a prototypical isoflavonoid, in the same 48 h model, with the 
addition of a neuroimmune component. Specifically, culture media was collected to 
assess for the release of the neuroimmune mediators HMGB1, TNF-α, IL-6, and IL-10 
via ELISA. Compound 9b and DZ protected against EtOH-induced cytotoxicity at 48 h. 
EtOH exposure significantly increased secretion of HMGB1 and IL-6 into culture media 
at 48h. Compound 9b and DZ attenuated these increases at all concentrations tested. 
These results suggest potential neuroimmune modulating properties of isoflavonoids 
which may contribute to their neuroprotective effects against EtOH in vitro. These 
findings highlight the potential applications DZ and the novel isoflavonoid analog 9b for 
use in the treatment of AUD. 
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CHAPTER ONE: Introduction to Alcohol Use Disorder 
1.1. Background and Significance  
1.1.1. Prevalence and Definition 
An estimated 13.9% of American adults currently meet Diagnostic and Statistical 
Manual of Mental Disorders-Fifth Edition (DSM-5) criteria for an alcohol use disorder 
(AUD) (Grant et al, 2015). This statistic is particularly worrisome as it indicates a 49.4% 
increase in current AUD status since 2001-2002 (2001-2002 and 2012-2013 
corresponding DSM-IV rates 8.5% and 12.7%, respectively) (Grant et al., 2017). AUD is 
defined by DSM-5 as a “maladaptive pattern of alcohol use, leading to clinically 
significant impairment or distress”. Specifically, AUD is defined by 11 diagnostic criteria 
including: drinking in a higher volume or longer than intended, spending significant time 
drinking or recovering after a drinking episode, preoccupation with thoughts of alcohol 
use, inability to reduce alcohol use, neglect or reduction in important activities as a result 
of use, or continuation of use, despite physical, psychological, or family problems 
induced or exacerbated due to alcohol, craving, tolerance, and withdrawal (American 
Psychiatric Association [DSM-5], 2013). While these criteria are similar to the previous 
DSM-IV criteria, the DSM-5 eliminates use of separate categories for alcohol abuse and 
dependence diagnoses, and instead allows for a spectrum of severity within the AUD 
diagnosis: mild (i.e., the presence of 2-3 symptoms) moderate (i.e., the presence of 4-5 
symptoms), and severe (i.e., the presence of 6 or more symptoms) (American Psychiatric 
Association [DSM-5], 2013). 
Increases in DSM-IV AUD during the past decade may partially reflect a 29.9% 
increase in high risk, or heavy, alcohol consumption during the same period (from 9.7% 
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 to 12.6%) (Grant et al., 2017). Specifically, according to the 2014 National Survey on 
Drug Use and Health (NSDUH), approximately 16 million Americans can currently be 
characterized as heavy drinkers, 1.3 million of which are adolescents (Center for 
Behavioral Health Statistics and Quality, 2015). In this particular study, heavy drinking 
was defined as having at least 5 binge drinking episodes in the past month (with a 
“binge” being further defined as 5 or more drinks/occasion) (Center for Behavioral 
Health Statistics and Quality, 2015). Notably, this does not reflect the National Institute 
on Alcohol Abuse and Alcoholism’s (NIAAA) revised definition of a binge drinking, 
which is simply any point at which a person’s blood alcohol concentration (BAC) 
exceeds 0.08% (the legal limit in the United States) during a drinking session, regardless 
of alcohol units consumed (National Institute on Alcohol Abuse and Alcoholism, 2004). 
Definitions aside, this increasing trend in heavy drinking is concerning, as binge drinking 
frequency has been correlated with an increased risk of AUD (Dawson & Archer, 1993). 
This risk is ever higher if alcohol drinking is initiated during adolescence (Grant & 
Dawson, 1997; Nixon & Mclain, 2010; Crews, Vetreno, Broadwater, & Robinson, 2016). 
Excessive alcohol use (including binge, underage, and pregnant alcohol consumption) 
also contributes to a significant economic burden, costing the United States 
approximately $249 billion in 2010 (Sacks, Gonzales, Bouchery, Tomedi, & Brewer, 
2015). This figure includes costs due to health care claims, criminal activity, property 
damage, fetal alcohol syndrome, loss of productivity, and mortality.  
Notably, among persons 12 years of age and older needing treatment for AUD, 
there was a self-indicated desire for effective pharmacotherapy-based treatment options 
in 2013 (Substance Abuse and Mental Health Services Administration (SAMHSA, 2014). 
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 Unfortunately, while there are currently 4 medications approved by the US Food and 
Drug Administration (FDA) to treat AUD: disulfiram (Antabuse©), naltrexone (Revia©, 
Vivitrol©), and acamprosate (Campral©), these treatments have proven inadequate (50-
80% reporting a relapse to alcohol use within 1 year) (Johnson, 2008; Moos and Moos, 
2006; Heinz et al., 2009). The lack of efficacy of these pharmacotherapies may be 
because they work at preventing future alcohol consumption by lowering its value to the 
user (for example, taking disulfiram will make someone feel sick who consumes alcohol), 
and not by targeting the underlying neurodegeneration (Koob & Le Moal, 1997; Van 
Skike et al., 2016). Thus, the development of novel pharmaceutical interventions is still 
needed to address this gap in care.   
 
1.1.2. Alcohol and Neurodegeneration 
Prolonged, excessive alcohol consumption can ultimately lead to significant brain 
damage. Neuropathological analyses of post-mortem alcoholic brains have revealed 
trends of localized atrophy, showing decreased white matter volume in the cerebral 
hemispheres (Harper, Kril, & Holloway, 1985),  decreased cerebellar volume (Sullivan, 
Mathalon, Lim, Marsh, & Pfefferbaum, 1998), increased ventricle size (Harper, Kril, & 
Holloway, 1985), demyelination of the mammillary bodies (Alling & Bostrom, 1980), 
and thinning of the corpus callosum (Harper & Kril, 1985). In kind, studies conducted 
using magnetic resonance imaging (MRI), functional magnetic resonance imaging 
(fMRI), or voxel-based morphometry (VBM) have also revealed abnormalities in brain 
morphology of alcoholics, including decreased cortical gray matter (Jernigan, Schafer, 
Butters, & Cermak, 1991; Fein et al., 2002; Mann et al., 2001; Mechtcheriakov et al., 
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 2006) and white matter (Pfefferbaum et al., 1992; Mechtcheriakov et al., 2006); 
decreased frontal lobe volume (Pfefferbaum, Sullivan, Mathalon, & Lim, 1997); 
reduction in hippocampal size (Sullivan, Marsh, Mathalon, Lim, & Pfefferbaum, 1995; 
Agartz, Momenan, Rawlings, Kerich, & Hommer, 1999; Bleich et al., 2003; Beresford et 
al., 2006; Mechtcheriakov et al., 2006; Wilson, Bair, Thomas, & Iacono, 2017); and 
cerebellar shrinkage (Sullivan, Rosenbloom, Serventi, Deshmukh, & Pfefferbaum, 2003; 
Mechtcheriakov et al., 2006). However, while the above studies have focused on the 
adult brain, it is worth noting that the adolescent brain may be more vulnerable to 
alcohol’s effects, as research has shown that several brain areas (e.g. prefrontal cortex, 
nucleus accumbens, hippocampus) are still developing and undergoing substantial 
changes during adolescence (Lenroot & Giedd, 2006; Bava & Tapert, 2010; Nixon & 
McClain, 2010; Arain et al., 2013). Nagel, Schweinsburg, Phan and Tapert (2005) found 
that adolescents with AUD have smaller left hippocampal volumes than non-drinking 
controls. However, other MRI studies suggest that adolescent-onset AUD may be 
required for the hippocampal volume loss observed in adulthood (De Bellis et al. 2000; 
Nagel et al., 2005; Ozsoy, Durak, & Esel, 2013). Furthermore, while there has been 
difficulty in delineating the exact association between alcohol and reduced brain 
volumes, a recent study by Wilson and colleagues (2018) used adolescent female twin-
pairs (ages 11-24) to reveal the greater alcohol-using twin had smaller hippocampal 
volumes than their co-twin, suggesting a direct alcohol-exposure related effect on 
reductions in hippocampal volume. In addition to these hippocampal effects, MRI studies 
also show adolescent binge drinking may be predictive of cerebellar, thalamus, putamen, 
and brain stem volume loss (Pfefferbaum et al., 1992; Fein et al., 2013; Lisdahl, Thayer, 
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Squeglia, McQueeny, & Tapert, 2013). Notably, there have been sex and age differences 
reported across both adult and adolescent studies, but these patterns have not been 
consistent (for a review, see Sullivan & Pfefferbaum, 2005; Ewing, Sakhardande, 
& Blakemore, 2014). 
Ultimately, chronic alcohol use results in cognitive deficits, with up to 85% of 
alcoholics exhibiting signs of cognitive decline (Parsons & Nixon, 1993). Notably, 
associations between the performance on neuropsychological tests (e.g., The Wisconsin 
Card Sorting Task, The Letter Fluency Test, The Stroop Task) and deficits in the superior 
vermis, cerebellum, frontal lobe, hippocampus, thalami, insula, pons, and brain stem, 
have been shown (Sullivan, Rosenbloom, & Pfefferbaum, 2000; Chanraud, et al., 2007; 
Ozoy et al., 2013). Cardinal behaviors of AUD, such as impaired judgment, blunted 
affect, reduced motivation, and distractibility, have been attributed to frontal lobe deficits 
(for a review, see Sullivan & Pfefferbaun, 2005). Cerebellar volume deficits have been 
shown to be predictive of executive visuospatial and balance impairments (Sullivan et al., 
2000; Sullivan et al., 2003).  Additionally, fMRI studies have found that alcoholic 
individuals perform worse than non-alcoholic individuals in terms of their finger tapping 
output, a measure of automatic processing and cerebellar inefficiency (Parks et al., 2003). 
Studies utilizing single photon emission computed tomography (SPECT) have shown less 
regional cerebral blood flow (rCBF) in the frontal lobes of alcoholics when compared to 
non-alcoholics (Nicolas et al., 1993); furthermore, this has been associated with lack of 
inhibition and deficits in short term memory (Noël et al, 2001). In adults, the duration and 
amount of alcohol consumed is associated with the severity of neurobehavioral deficits 
(Parsons & Leber, 1981; Basso & Bornstein, 2000; Dwivedi, Chatterjee, & Singh, 2017). 
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Secondary disease states related to alcohol consumption, such as Korsakoff’s syndrome, 
Wernicke’s encephalopathy, and fetal alcohol spectrum disorder (FASD), can also 
contribute to alcohol’s neurobehavioral effects (for a review, see de la Monte & Kril, 
2014). 
1.1.3. Mechanisms of Alcohol-Induced Neurotoxicity 
There is significant difficulty in developing a successful treatment for AUD, as 
alcohol (referred interchangeably as “ethanol” [EtOH] in preclinical studies) does not act 
at one specific target, but rather exerts widespread effects on the CNS, interacting with 
multiple neurotransmitter systems, ion channels, and signaling pathways (for a full 
review see, Nevo & Hamon, 2004; Chastain, 2006; Ward, Lallemand, & Witte, 2009). 
While the exact neurochemical processes leading to EtOH’s neurodegenerative effects 
have remained elusive, extensive research has demonstrated a role for oxidative stress 
(Ramachandrin et al., 2003; Hamelink, Hampson, Wink, Eiden, & Eskay, 2005; Collins 
& Neafsey, 2012), pro-inflammatory neuroimmune signaling (Blanco, Valles, Pascual, & 
Guerri, 2005; Fernandez-Lizarbe, Pascual, and Guerri, 2009; Alfonso-Loeches, Pascual-
Lucas, Blanco, Sanchez-Vera, & Guerri, 2010; Pascual, Baliño, Alfonso-Loeches, 
Aragón, & Guerri, 2011; Crews et al., 2015), and excitotoxicity (Lovinger, 1993; Davis 
& Wu, 2001; Nagy & Laszlo, 2002; Prendergast et al., 2004) in the promotion of EtOH-
induced neurotoxicity during different phases of dependence. Specifically, oxidative 
stress and pro-inflammatory neuroimmune signaling have been shown to contribute to 
neurotoxicity observed during periods of EtOH exposure (Ramachandrin et al., 2003; 
Hamelink et al., 2005; Collins & Neafsey, 2012; Crews et al., 2015). In contrast, 
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excitotoxicity is associated with the increased neurotoxicity observed during EtOH-
withdrawal (EWD) (Davidson, Shanley, & Wilce, 1995; Harris et al., 2003; Prendergast 
et al., 2004).  However, overlap between these mechanisms does exists (for a review, see 
Fadda & Rossetti, 1998; Crews et al., 2015), suggesting there are likely several common 
targets which could be exploited for drug development. The below sections will briefly 
discuss these mechanisms of EtOH-induced neurotoxicity, as well as discuss possible 
interactions.  
1.1.3.1. Oxidative Stress. Oxidative stress-induced mitochondrial damage is 
implicated in the development of several neurodegenerative diseases (Barnham, Masters, 
& Bush, 2004; Lin & Beal, 2006), and occurs when the generation of reactive oxygen 
species (ROS) exceeds the endogenous antioxidant control mechanisms (Battino, Bullon, 
Wilson, & Newman, 1999). EtOH can potentiate ROS levels through multiple routes, 
including oxidation in the brain via metabolism in the brain by CYP 2E1 (Zimatkin, 
Pronko, Vasiliou, Gonzalez, & Deitrich, 2006); induction of NADPH/xanthine oxidase 
(NOX/XOX) and nitric oxide synthase (NOS) in neurons and microglia (Haorah, Schall, 
Ramirez, & Persidsky, 2008; Qin & Crews, 2012); and depletion of the endogenous 
scavenger and antioxidant systems responsible for the regulation of these ROS (Guerri & 
Grisolio, 1980; Schlorff, Husain, & Somani, 1999). Chronic EtOH exposure has been 
shown to lead to increases in ROS and reactive nitrogen species (RNS), inducing 
oxidative stress (Nordmann, Ribière, & Rouach, 1992; Haorah, Schall, Ramirez, & 
Persidsky, 2008). In addition to oxidative stress, this imbalance can initiate a number of 
cascades, including mitochondrial dysfunction. Ramachandrin and colleagues (2003) 
7 
found that EtOH-induced oxidative stress directly initiated mitochondrial apoptosis 
pathways in cultured fetal cortical rat neurons. Obernier, Bouldin, and Crews (2002) 
found that adult rats experienced neurodegeneration in their olfactory bulbs after only 2 
days of binge EtOH exposure, and these deficits extended throughout additional brain 
regions, including the hippocampus, after 4 days of binge EtOH exposure. Furthermore, 
the neurodegeneration was not observed to be exacerbated by an EWD period (Obernier 
et al., 2002), suggesting a mechanism of neurotoxicity independent of excitotoxicity. 
Additional studies have demonstrated that the potent antioxidants, butylated 
hydroxytoluene (BHT) and α-tocopherol, can block binge EtOH-induced 
neurodegeneration in the rat hippocampus and entorhinal cortex in vivo (Hamelink et al., 
2005). In kind, our lab has found that the potent antioxidant, Trolox, blocks cytotoxicity 
produced by a 48 h binge-like EtOH exposure in OHSC (Saunders, 2016). These findings 
support the role of oxidative stress and mitochondrial pathways in EtOH-induced 
neurotoxicity.  
1.1.3.2. Neuroimmune Signaling. While glial activation (both microglia and 
astrocytes) plays an important neuroprotective role in response to harmful stimuli 
(Cherry, Olschowka, & O’Banion, 2014), sustained neuroimmune responses contribute to 
the progression of neurodegenerative disease (Giovannini et al., 2003; Hunot & Hirsche, 
2003; Frank-Cannon, Alto, McAlpine, & Tansey, 2009), brain injury (Schmidt, Infanger, 
Heyde,  Ertel, & Stahel, 2004; Cherry, Olschowka, & O’Banion, 2014), and psychiatric 
disorders (Lucas, Rothwell, & Gibson, 2006). Microglia are the primary mediators of the 
brain’s innate immune systems (Rivest, 2009), and are commonly categorized as 
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 classic/proinflammatory (M1) or alternate/anti-inflammatory (M2) based on their 
observable morphology (Colton, 2009; Michelucci, Heurtaux, Grandbarbe, Morga, & 
Heuschling, 2009). Notably, these classifications are considered somewhat 
oversimplified, as intermediate phenotypes do exist (Hu et al., 2015; Jha, Lee, & Suk, 
2016; Orihuela, McPherson, & Harry, 2016; Ransohoff, 2016). Post-mortem alcoholic 
brains show increased microglial activation and astrogliosis (He & Crews, 2008). 
Increased markers for the pro-inflammatory transcription factor nuclear factor kappa-
light-chain-enhancers of activated B cells (NF-κB) (Liu & Malik, 2006; Ökvist et al., 
2007) and upregulated neuroimmune gene expression have also been observed (He & 
Crews, 2008).  
In pre-clinical studies, activation of a second pro-inflammatory transcription 
factor, activator protein 1 (AP-1), has also been observed in response to EtOH (Fried, 
Kotarsky, & Alling, 2001; Blanco, et al., 2005). Both NF-κB and AP-1 are known to 
increase the expression of cytokines (TNF-a, IL-1β, IL-6, MCP-1), and these effects are 
associated with inflammation and cell death (for a review, see Blanco & Guerri, 2006). 
Notably, the regulation of the immune response by EtOH is complex, depending on the 
dose, duration of EtOH treatment (binge vs. chronic), and model. A single (acute) binge 
EtOH exposure in vitro and in vivo has been shown to suppress the innate immune 
response peripherally in mice and in macrophage cultures, as measured a reduction in the 
expression of TNF-α, IL-1β, and IL-6 mRNA in response to lipopolysaccharide (LPS), an 
endotoxin used to induce inflammation (Pruett, Schwab, Zheng, & Fan, 2004; Goral, 
Choudhry, & Kovacs, 2004). Moreover, Suryanarayanan and colleagues (2016) have 
shown that IL-10, an anti-inflammatory cytokine, is upregulated in the rat hippocampus 
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as soon as 1 h following the oral administration of a single intoxication dose of EtOH. 
However, while induction NF-κB DNA binding is required for expression of TNF-α, IL-
1β, and IL-6, studies suggest that acute binge EtOH exposure does not inhibit NF-κB 
activity in vivo (Ward et al., 1996; Pruett & Fan, 2009) or in vitro (Davis & Syapin, 2004; 
Blanco et al., 2005). In kind, Doremus-Fitzwater, Gano, Paniccia, and Deak (2015) have 
shown that acute EtOH decreases mRNA expression for IL-1 and TNFα, IL-6 mRNA is 
actually upregulated, especially in the hippocampus of adult rats. Notably, mRNA 
expression is only predictive of outcome protein expression ~40% of the time (Kendrick, 
2014). A study by Marshall, Geil, and Nixon (2016) suggests this acute activation may 
lead to primed (i.e., more susceptible) microglia, as a subsequent binge EtOH treatment 
revealed both a potentiated classically activated microglial response and increased release 
of TNF-α in the rat hippocampus. This finding is consistent with chronic in vitro and in 
vivo EtOH exposure models which show an increase in NF-κB and AP-1-mediated 
transcription of pro-inflammatory genes in astrocytes, microglia, and slice culture (Ward 
et al., 1996; Vallés, Blanco, Pascual, & Guerri, 2004). Notably, the previous studies have 
focused on single cell models or the hippocampus, however, interactions between several 
neurotransmitters (e.g., serotonin, dopamine, GABA) and cytokines (e.g., IL-1β, IL-6, 
TNF-α) have also been observed in brain regions associated with EtOH reward, including 
the amygdala, lateral hypothalamus, and nucleus accumbens (Brebner, Hayley, Zacharko, 
Merali, & Anisman, 2000; Knapp et al., 2011). While the direct relationship between 
EtOH-induced cytokine release and neurodegeneration is not well characterized, LPS-
evoked TNF-α has been shown to cause cytotoxicity in dopamine cells (Harms et al., 
2012). Interestingly, astroglia and microglia of mice deficient in, or with knock-out of, 
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 toll-like receptor 4 (TLR4), the canonical mechanism of NF-κB activation (Hoesel & 
Schmid, 2013), were protected against EtOH-induced apoptotic cell death (Blanco et al., 
2005; Fernandez-Lizarbe, et al., 2009; Alfonso-Loeches et al., 2010; Pascual et al., 2011). 
The Integrative Neuroscience Initiative on Alcoholism (INIA-Neuroimmune) consortium 
has recently presented a series of studies demonstrating no significant impact of the 
TLR4 on EtOH drinking behavior in models of CIE exposure; notably, mice and rats 
received NAcc-specific knock-out (KO) of the TLR4 in these studies (Harris et al., 2017). 
However, Pascual and colleagues (2011) have shown  that TLR4 KO mice exhibit less 
EtOH-induced cognitive and motor impairments than wild type mice in a model of 
chronic EtOH drinking and subsequent EWD (Pascual et al., 2011). Additionally, 
amygdala-specific TLR4 inhibition in alcohol preferring (P) rats has been shown to 
reduce EtOH self-administration (Liu et al., 2011).  
However, Alfonso-Loeches and colleagues (2010) found that activation of NF-κB 
in response to chronic EtOH exposure was associated with both increased levels of IL-1β, 
TNF-α, IL-6, and several oxidases (e.g.,  COX-2 and iNOS) in the cerebral cortex of 
female wide-type mice. This increase in COX-2 and iNOS by NF-κB could lead to 
oxidative stress through the generation of ROS (Sun et al., 2001). As ROS can directly 
activate NF-κB, oxidative stress may contribute to the persistent innate immune response 
observed following chronic EtOH consumption (Qin & Crews, 2012). These findings 
already suggest significant interactions with other mechanisms in the promotion of 
EtOH-induced neurotoxicity. In support, Crews and colleagues (2006) found that 
treatment with BHT, a potent antioxidant, during binge EtOH exposure reduced NF-κB 
activation and COX-2 expression in the hippocampus of adult male Sprague-Dawley rats. 
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Furthermore, this reduction was associated with a reversal in binge EtOH-induced brain 
damage (Crews et al., 2006). More recently, 2 additional antioxidants, EUK-134 and 
Trolox, were shown to protect EtOH-treated microglia from oxidative stress and 
apoptosis-induced cell death (Boyadjieva & Sarkar, 2013). These studies support a 
neuroimmune mechanism in EtOH-induced neurotoxicity. Additionally, they suggest that 
interactions may exist between oxidative stress and neuroimmune signaling to promote 
this neurotoxicity.   
1.1.3.3. Excitotoxicity. Although both acute and chronic EtOH exposure alter the 
expression and/or function of many receptor subtypes, withdrawal from chronic EtOH is 
known to be particularly detrimental, resulting in severe symptoms in both humans and 
animals including, anxiety, hypoactivity, agitation, insomnia, tremor, seizures, delirium, 
and in some cases, death (Grant Valverius, Hudspith, & Tabakoff, 1990; Davidson et al., 
1995; Trevisan, Boutros, Petrakis, & Krystal, 1998). The ionotrophic N-methyl-D-
aspartate receptor (NMDAR), a glutamate receptor involved in controlling synaptic 
plasticity and learning, and may be involved in promoting the cognitive deficits observed 
following chronic alcohol use (Hoffman & Tabakoff, 1994). NMDAR are heteromeric in 
structure, consisting of three different subunits (NR1, NR2, and NR3), with mammalian 
cells consisting of at least one NR1 subunit and one NR2 (A-D) subunit (for a review, see 
Paoletti & Neyton, 2007). Notably, the NR2A and NR2B subunits have been shown to be 
the most polyamine (and glutamate)-sensitive subunits, and thus, are the mostly widely 
studied in regards to alcohol’s effects on the brain (Mirshahi & Woodward, 1995). Acute 
EtOH exposure reduces excitatory glutamatergic synaptic transmission by inhibiting 
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NMDAR function, which alters intracellular calcium (Ca2+) levels and modifies 
downstream cell-signaling cascades, such as phosphorylation (Lovinger, 1993; Tsai, 
1998; Davis & Wu, 2001; Ron, 2004). As a result, chronic EtOH administration results in 
a compensatory upregulated expression in NMDARs with an EtOH-sensitive NR1/NR2B 
subunit conformation (Lovinger, 1993; Tsai, 1998; Wirkner et al., 1999; Davis & Wu, 
2001; Nagy & Laszlo, 2002; Ron, 2004). Antagonism of the NMDAR during chronic 
EtOH exposure is known to reduce EWD-induced neuronal hyperexcitability in vitro 
(Thomas, Monaghan, & Morrisett, 1998). Additionally, our lab has previously shown that 
excitotoxicity during EWD from continuous EtOH exposure is dependent on this increase 
in NR1/NR2B subunits in OHSC (Harris et al., 2003; Prendergast et al., 2004). Using a 
chronic intermittent EtOH (CIE) treatment regimen, characterized by cycles of binge-like 
exposure and EWD, we have also found that co-exposure to the NMDAR antagonist 
APV during periods of EWD prevents hippocampal cell death (Reynolds, Berry, Sharrett-
Field, & Prendergast, 2015). In rodents, altered glutamatergic activity has been shown to 
lead to a prolonged upregulation of sensitized NMDARs (Rani & Ticku, 2006), resulting 
in increased withdrawal severity (Veatch & Becker, 2002), alcohol-seeking (Griffin, 
Lopez, Yanke, Middaugh, & Becker, 2009), and relapse to EtOH (Wang et al., 2010). 
Antagonism of the NMDAR during chronic EtOH exposure has been shown to reduce 
EWD-induced seizure activity in rats (Morrisett et al., 1990).  However, this reduction in 
seizure activity through blockade of the NMDAR does not affect EtOH self-
administration (Bienkowski et al., 2001).  
EWD-induced excitotoxicity is also associated with alterations in intracellular 
Ca2+ signaling (Prendergast et al., 2004; Lau & Tymianski, 2010), and EWD-induced 
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 Ca2+ influx can be inhibited by NMDAR antagonists in OHSC (Mayer et al., 2002).  This 
influx of Ca2+ ultimately leads to dysregulated calcium homeostasis, and this imbalance 
can initiate a number of cascades, including mitochondrial dysfunction function, 
oxidative stress, and cell death (as discussed above in the Oxidative Stress section). 
However, mitochondrial dysfunction and oxidative stress have also been shown to 
activate the protease, calpain, which can directly upregulate EtOH-sensitive NMDA 
NR2B subunits (Norberg et al., 2008). Sunkesula, Swain and Babu (2002) found an up-
regulation of NMDA NR1, 2B, and 2C subunits in the hippocampus following a 12 week 
continuous EtOH exposure period in adult rats. Notably, an up-regulation of proteases 
such as calpain and caspase were also observed, suggesting mitochondrial involvement 
(Sunkesula et al., 2002). In support, data which are currently in preparation from our lab, 
indicate that antagonism of calpain completely prevents EWD-induced loss of synaptic 
vesicle protein, an indicator of axon integrity and neurotoxicity (Saunders et al., in 
preparation).  
TLR4 signaling, through upregulation of the TLR4 agonist high-mobility group 
box 1 (HMGB1), has also been shown to potentiate EtOH-induced CA2+ influx and 
excitotoxicity (Viviani et al., 2003; Vezzani, Maroso, Balosso, Sanchez, & Bartfai, 2011; 
Balosso, Liu, Bianchi, & Vezzani, 2014). Furthermore, greater HMGB1 release has been 
shown in response to EWD (Whitman, Knapp, Werner, Crews, & Breese, 2013), and 
studies have found increased HMGB1 to be associated with hippocampal excitability and 
seizures in a model of epilepsy (Maroso et al., 2011). Furthermore, upregulations in 
HMGB1 were shown to be persistent following hippocampal excitability (Maroso et al., 
2011), suggesting a feed-forward cycle may exist between neuroimmune responses and 
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excitotoxicity. In kind, chronic EtOH exposure has been shown to result in TNF-α-
mediated inhibition of glial glutamate transporters, thus preventing uptake of glutamate 
from the synapse, and potentiating EWD-induced excitotoxicity in hippocampal-
entorhinal (HEC) slice cultures (Zou & Crews, 2005; 2010).  
Collectively, these studies suggest that EtOH exposure results in neuroadaptations 
that interact to promote excitotoxicity during EWD. Furthermore, it suggests that 
excitotoxicity may be secondary to oxidative stress and pro-inflammatory neuroimmune 
signaling in response to EtOH. Therefore, therapeutic strategies which address 
mechanisms of toxicity during EtOH exposure could be effective at ameliorating the 
toxicity of both phases of dependence.  
 1.2. The Current Project 
Collectively, this review demonstrates that chronic, excessive alcohol consumption 
predicts worse neurological outcome in the clinical AUD population. Unfortunately, the 
current pharmacotherapies for AUD work at preventing future alcohol consumption by 
lowering its value to the user, and not by targeting the underlying neurodegeneration 
(Koob & Le Moal, 1997; Van Skike et al., 2016). Thus, the development of novel 
pharmaceutical interventions is still needed to address this gap in care. 
Pharmacotherapies which address events that alter neuroplasticity, such as 
neurodegeneration and neuroinflammation, may improve treatment outcomes for AUD 
(Koob & Le Moal, 1997). Further, as reward and cognitive circuits overlap, there are 
likely several common targets which could be exploited for drug development (Adinoff, 
2004). Natural product compounds have presented themselves as appealing drug 
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 discovery targets in recent years, having greater structural diversity and increased 
therapeutic success compared to synthetic compounds (for a review see, Harvey, 2008). 
Moreover, development of synthetic natural product analogs allows for molecular 
modifications which can: 1) enhance desired bioactivity, 2) add mechanisms of action, 
and/or 3) improve solubility and metabolism (Kerns & Di, 2003). Despite this, natural 
products and their analogs remain an untapped resource in drug discovery and 
development for AUD. The purpose of the present dissertation is to identify novel 
chemical scaffolds which may be exploited in the development of pharmacological 
treatments for AUD. Thus, Study 1 presents the discovery of several natural product 
analogs which attenuate EtOH-induced cytotoxicity in vitro. Study 2 extends these 
findings by discussing the role of neuroimmune signaling in the development of EtOH-
induced neurotoxicity and evaluating the effects of 1 lead candidate compound, identified 
in Study 1, on neuroimmune mediators released into culture media during the same 










 CHAPTER TWO: Study One: Effect of Novel Natural Product Analogs on Binge 
Ethanol-Induced Cytotoxicity In Vitro 
Sections of this chapter have been previously published and reprinted with permission 
from Zhang, J., Hughes, R.R., Saunders, M.A., Elshahawi, S.I., Ponomareva, L.V., 
Zhang, Y., ... & Thorson, J.S. (2017). Identification of Neuroprotective Spoxazomicin 
and Oxachelin Glycosides via Chemoenzymatic Glycosyl-Scanning. Journal of natural 
products, 80(1), 12-18. Copyright 2018 American Chemical Society. 
 
2.1. Introduction 
The development of novel drugs is a high-risk endeavor which requires 
multidisciplinary collaboration across several scientific fields (e.g. chemists, biologists, 
psychopharmacologists) and procures an average cost of $2.6 billion per new market 
drug in the United States (DiMasi, Hanson, & Grabowski, 2003). Drug research and 
development (R&D) requires multiple steps from target screening, to clinical trials, to the 
evaluation of drug efficacy in human participants (Kelly, 2009). While many of these 
R&D projects are initiated, only a fraction succeeds through clinical trials, which may 
require the screening of thousands of compounds in the hope of finding different classes 
of drugs that work within a desired model (Kelly, 2009). Furthermore, initiation of a 
project through drug sale may take an average of 15 years following the identification of 
a viable compound candidate (called a “hit”) (Levy, 2000).  A hit may go through to 
subsequent testing phases in the structural form it was identified; however, it is also 
common for the structure of the compound to be modified for changes which may further 
improve its efficacy in the model. This newly modified compound may then be re-
evaluated for efficacy in all testing phases. Once a hit compound is advanced into further 
testing phases, it may be referred to as a “lead” compound. As model systems do not 
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 perfectly predict therapeutic action in the clinical trial setting, it is important to generate 
numerous lead compounds, taking into account structural diversity amongst these 
compounds before the investment into animal models and clinical trial phases are made 
within an R&D project (Kelly, 2009).  
Specifically, to gain FDA approval, a hit compound must be evaluated in, and 
successfully advance through Absorption, Distribution, Metabolism, Excretion (ADME) 
and Toxicology safety tests, preclinical testing, and four clinical trial phases. Rules, such 
as Lipinski’s Rule of Five, have been developed which help in ADME consideration and 
improve the predictability of preclinical and clinical trial outcomes. Lipinski’s rule is 
used to assess a chemical compound’s “drug-likeness” and whether it possesses 
pharmacological or biological activity that is predictive of an orally active drug in 
humans. A compound is more likely to have poor absorption and permeability when:  (1) 
there are more than 5 hydrogen bond donors, (2) the molecular mass is greater than 500 
daltons, (3) there are more than 10 hydrogen bond acceptors, (4) the calculated log P is 
greater than 5, and (5) natural product compounds, as well as any compounds which are 
substrates for biological transport systems, are exempt from these rules (Lipinski, 
Lombardo, Dominy, & Feeney, 2001). This suggests an advantage for natural product 
compounds, over synthetic compounds, going into the screening process (Newman, 
2008).  
Natural products have been exploited for their medicinal properties as far back as 
2600 BCE in ancient Mesopotamia (Borchardt, 2002). Currently, approximately 60% of 
drugs on the market are directly or indirectly derived from natural product sources 
(Newman, 2008). Notably, in the 1990’s, the medical field shifted away from the 
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 screening of natural product compounds to high-throughput screening (HTS) of 
combinatorial chemistry libraries due lower costs. Since this shift, fewer medications 
have successfully gained FDA approval, resulting in what has been deemed a 
“development pipeline”. Many have pointed out a lack of diversity and complexity 
amongst combinatorial chemistry libraries (Ji, Li, & Zhang, 2009; Newman & Cragg, 
2007). Natural product compound libraries present with increased diversity over synthetic 
libraries as natural product compounds are simply spatially more diverse than synthetic 
compounds in respect to the number of chiral structures, rings, bridges, and functional 
groups in the molecule (Henkel, Brunne, Müller, & Reichel, 1999). Chirality is 
particularly interesting as this is when a compound has 4 different groups around a 
central atom (assuming carbon) and presents an asymmetric structure; the unique 
structure of these molecules could be particularly beneficial in CNS drug R & D as they 
may provide a superior fit to receptors and other target proteins due to these different 
functional groups coming off the central atom (Mentel, Blankenfeldt, & Breinbauer, 
2009). Additionally, natural products tend to be highly soluble in aqueous media, a 
feature not seen with many synthetic compounds, and which is desirable in drug 
formulations as it predicts absorption (Krishnaiah, 2010).  
However, more recent knowledge of natural chemical structures has allowed for 
the synthesis of natural structures at the bench top, relieving the need for constant 
isolation from natural sources. These new developments in chemistry have significantly 
reduced the cost of screening natural product compound libraries (for a review, see 
Harvey, 2008). Moreover, chemists have developed strategies to create compound 
analogs and derivatives (i.e., compounds which are similar to, but differ from the parental 
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 compound by at least a single element group) with an increased therapeutic potential over 
their original structures (Sunazuka, Hirose, & Omura, 2008). Specifically, the 
development of natural product analogs allows for additional molecular modifications 
which can: 1) enhance desired bioactivity, 2) add mechanisms of action, and/or 3) 
improve solubility and metabolism (Kerns & Di, 2003). These developments have given 
researchers access to compounds that have greater diversity in structure, as well as unique 
chemical properties which lend them to be more readily absorbed than purely synthetic 
compounds (for a review, see Harvey, 2008). The combination of these two factors has 
revived interest in the use of natural product compounds and their synthetic analogs in 
drug discovery (Galm & Shen, 2007).  
 
2.2. Experimental Rationale 
Natural product compounds represent an untapped resource within AUD drug 
discovery, as the more complex chiral structures of these compounds may provide a 
superior fit to receptors and other target proteins (Mentel et al., 2009). As discussed in 
Chapter 1, addressing the underlying neurobiological deficits induced by AUD may be an 
essential feature of an effective pharmacotherapy. Notably, HTS techniques employed 
during drug R & D are typically employed in single cell models where the target of 
interest is known. However, cells and tissues are physiologically connected, and these 
interactions are important to the progression of many disease states (Giacomotto & 
Ségalat, 2010). For these reasons, HTS techniques are not applicable in the early stages 
of new drug development for diseases in which these interactions are known. In AUD, 
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 neuron-glia interactions are critical in the progression of AUD neuropathology (for a 
review, see Crews et al., 2015). The organotypic hippocampal slice culture (OHSC) 
technique allows for the reliable replication of neuronal over-activation in the 
hippocampus that can be translated in vivo (Gahwiler, Capogna, Debanne, McKinney, & 
Thompson, 1997; Noraberg et al., 2005; Sharrett-Field, Butler, Berry, Reynolds, & 
Prendergast, 2013; Reynolds, Williams, Saunders, & Prendergast, 2015; Reynolds, 
Saunders, & Prendergast, 2016), and has been validated in the examination of EtOH-
induced neurodegeneration (Bulter et al., 2013; Reynolds et al., 2015a; Reynolds et al., 
2016). Specifically, this model preserves hippocampal neuropil layers, and thus, is ideal 
for the employment of immunohistochemical staining (Noraberg et al., 2005), the 
quantification of compromised neurons (Noraberg, Kristensen, & Zimmer, 1999), and 
viewing of localized cell death (Noraberg, Kristensen, & Zimmer, 1999). Furthermore, 
the OHSC technique has been used to measure EtOH-induced neuroimmune signaling 
(Moon et al., 2014; Lutz, Carter, Fields, Barron, & Littleton, 2015a,b), and important 
neuron-glia interactions are preserved in this model (Benediktsson, Schachtele, Green, & 
Dailey, 2005; Haber,  Vautrin, Fry, & Murai, 2009; Dailey & Waite, 1999). Moreover, 
beyond being validated as a model for the examination EtOH-induced changes in the 
brain, deficits observed in the hippocampal brain region of alcoholics is thought to 
contribute to neurobehavioral consequences (Sullivan, Rosenbloom, & Pfefferbaum, 
2000; Chanraud, et al., 2007; Pitel et al., 2007; Ozoy et al., 2013), including deficits in 
reward sensitivity (Makris et al., 2008) and enhancement of drug-context associations 
which could facilitate relapse and maintenance of alcohol use (Müller, 2013; Kutlu & 
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 Gould, 2016). Collectively, this suggests the OHSC model is an ideal model for the 
screening of novel compound candidates in the early drug development stages for AUD.   
In collaboration with scientists at the University of Kentucky Center for 
Pharmaceutical Research and Innovation (CPRI), our lab has previously screened several 
compounds from the CPRI natural products repository for their ability to attenuate 48 h 
EtOH (100 mM)-induced increases in propidium iodide (PI) uptake in a rat OHSC model 
(Wang et al., 2015; Shaaban et al., 2017; Zhang et al., 2017). PI allows for the 
quantification of cytotoxicity as it can only enter cells with disrupted plasma membranes, 
reflecting the presence of necrotic or end-stage apoptotic cells within the primary 
neuronal and glial cell layers of hippocampal cultures (for a review, see Zimmer, 
Kristensen, Jakobsen, & Noraberg, 2000). Prior work has shown a 48 h binge EtOH 
exposure is sufficient to produce necrosis-induced degeneration in the olfactory bulbs of 
adult rats in vivo (Obernier et al., 2002), and that in vivo binge EtOH exposure in 
adolescent rats produces hippocampal-dependent learning and memory deficit in 
adulthood similar to those observed in clinical AUD populations (Vetreno & Crews, 
2015). Terfestatin B, a natural product compound isolated from Streptomyces sp. RM-5-8 
(Wang et al., 2015), and both spoxamicin D and oxachelin C, natural product compounds 
isolated from Streptomyces sp. RM-14-6 (Shaaban et al., 2017), were found to have 
cytoprotective effects in our model. As the creation of natural product compound analogs 
can result in compounds with enhanced-desired characteristics (Kerns & Di, 2003), the 
purpose of the present study was to screen novel analogs of previously identified natural 
product compounds (from both our lab and others) for their ability to attenuate binge-like 
EtOH-induced hippocampal cytotoxicity in vitro. The hypothesis of the current study is 
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 that analogs of natural products previously shown to attenuate EtOH-induced 
neurodegeneration or neurobehavioral deficits will attenuate EtOH-induced cytotoxicity 
with enhanced efficacy over their parental compound structures.  
 
2.3. Method 
2.3.1. Organotypic Hippocampal Slice Culture Preparation 
Male and female Sprague-Dawley rat pups (i.e., 8 days old) (Harlan Laboratories; 
Indianapolis, IN) were humanely sacrificed. Whole brains were aseptically removed 
(after Mulholland et al., 2005) and immediately placed into culture dishes containing 
chilled dissecting medium composed of Minimum Essential Medium (MEM; Invitrogen, 
Carlsbad, CA), 25 mM HEPES (Sigma, St. Louis, MO), 21.20 µM Amphotericin B 
solution (Sigma), and 50 µM streptomycin/penicillin (Invitrogen). Bilateral hippocampi 
were removed and placed into culture dishes containing chilled culture medium 
composed of dissecting medium, double distilled water, 36 mM glucose (Fisher, 
Pittsburg, PA), 25% Hanks’ Balanced Salt Solution (HBSS; Invitrogen), 25% (v/v) heat-
inactivated horse serum (HIHS; Sigma), 0.05% Amphotericin B solution (Sigma), and 
0.10% streptomycin/penicillin (Invitrogen). Excess tissue attached to hippocampi was 
carefully removed with the use of a stereoscopic microscope. Each hippocampus was 
then coronally sectioned at 200 µm thickness using a McIllwain Tissue Chopper (Mickle 
Laboratory Engineering Co. Ltd., Gomshall, UK) and transferred to a culture dish 
containing chilled culture medium. Hippocampal slices were selected for inclusion of all 
three hippocampal regions (CA1, CA3, and dentate gyrus) through examination under a 
stereoscopic microscope. Following selection, 3-4 slices were plated onto Millicell-CM 
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 0.4 µM biopore membrane inserts sitting in 35-mm 6-well culture plates containing 1 mL 
of pre-incubated culture medium. This method produces 18-24 intact hippocampal slices 
per 6-well plate. To allow for air exposure, all excess culture medium was carefully 
removed from the top of each culture well. To allow hippocampal slices to adhere to the 
biopore membrane inserts, the tissue was stored in an incubator at 37°C with a gas 
composition of 5% CO2/95% air for 5 days before experiments were conducted. Care of 
all animals was carried out in agreement with the University of Kentucky’s Institutional 
Animal Care and Use Committee.  
 
2.3.2. EtOH and Compound Analog Treatment 
Natural product analog compounds (~20) from the natural and synthetic products 
repository, including those derived from Streptomyces sp. RM-5-8 (Wang et al., 2015) 
and Streptomyces sp. RM-14-6 (Shaaban et al., 2017; Zhang et al., 2017), have been 
provided to our laboratory by the University of Kentucky Center for Pharmaceutical 
Research and Innovation (CPRI). Compound analogs were pre-screened for in silico 
blood brain barrier (BBB) permeability, and only compounds found to have a predicted 
probability value > 0.90 (according to the admetSAR model; Cheng et al., 2012), were 
provided by the CPRI. The activity of compound parental structures in various EtOH 
treatment models is presented in Table 2.1. Where allowed, a description of each 
compound analog’s unique structure can be seen in Figure 2.1. The parent and analog 
structures for compounds 1, 6, 7, 10, and 11 were withheld at the request of the CPRI to 
preserve intellectual property (IP). Compound analogs were delivered with their 
structures blinded via arbitrary compound naming. At 5 days in vitro (DIV), after the 
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 hippocampal slices had adhered to the biopore membrane, cultures were transferred at 
random to 6-well culture plates containing 1 mL of culture medium with 0.01% dimethyl 
sulfoxide (DMSO vehicle control [CTRL]; Fisher) or 1 mL of culture medium with the 
addition of 0.01% DMSO and 100 mM EtOH (a concentration that represents 6x the legal 
limit in humans [480 mg/dL]). While this concentration is high, a case study of 117 
alcoholic patients found BACs ranging from 29 to 577 mg/dL upon hospital admittance, 
with many of these patients still walking and cognizant with BACs over 300 mg/dl 
(Adachi et al., 1991). Additional cultures were exposed to CTRL or EtOH (100 mM) 
medium with the addition of a product analog at multiple concentrations (0.01-1.0 µM) to 
establish concentration-response relationships. Compounds were provided by the CPRI in 
10 mM DMSO stock solutions which were diluted in culture medium to a final DMSO 
concentration of 0.01%. All culture medium also received the addition of propidium 
iodide (PI; 7.48 μM) during the 48 h exposure (discussed below in Measurement of 
Cytotoxicity via Propidium Iodide Staining). In order to prevent diffusion of EtOH from 
the culture medium, all EtOH treated plates were placed into topless polypropylene 
containers containing 50 mL of ddH2O with the addition of 100 mM EtOH. CTRL groups 
received similar treatment, without the addition of EtOH. Containers were then placed 
into sealable 1-gallon freezer bags and filled with compressed gas (5% carbon 
dioxide/95% air), to mimic the incubator conditions, and returned to the incubator for 48 
h. Attempts were made to prevent evaporation of EtOH at every step of this procedure, 
however, prior work suggests ~10% reduction in the final starting concentration of EtOH 






Table 2.1. Activity of compound parental structures in various ethanol treatment models.   
Compound Parent Structure Population Method Effect Observed References 
1 withheld – – – – 
2a 
Spoxazomicin C* SD OHSC Inactive  Shaaban et al., 2017 2b 
2c 
3 N-salicyloyl-2-aminopropane-1,3-diol* – excluded initially  – Zhang et al., 2017 
4a (2R)-N-salicyloyl-2-
aminopropan-1-ol* – excluded initially – Zhang et al., 2017  4b 
5a Oxachelin┼ SD OHSC Inactive  Shaaban et al., 2017 5b 
6 withheld – – – – 
7 withheld – – – – 
8a Terfestatin B SD OHSC ↓ binge EtOH-induced cytotoxicity Wang et al., 2015 8b 
9a 
Isoflavonoid 
SD OHSC Rhamnetin ↓ EWD cytotoxicity Lutz et al., 2015a 
9b SD EtOH (7%, w/v) continuous  50 and 150 mg/kg ip puerarin ↓ EWD  Overstreet et al., 2003 
9c P-rats  EtOH (10% w/v) 2-bottle, free-choice Daidzin, daidzein, and puerarin 
↓ EtOH intake Lin & Li, 1998 
9d P-rats EtOH (15% w/v) 2-bottle, free-choice 0.5 g/kg kudzu root ↓ EtOH 
intake, ↓ EWD Benlhabib et al., 2004 
9e Heavy Drinkers  
Pilot and randomized between-subject, 
double-blind, placebo-controlled study 
750-1200 mg daily isoflavone ↓ 
EtOH intake 
Lukas et al., 2005; 2013; 
Penetar et al., 2012 
9f Male Binge Drinkers  
Double-blind, placebo-controlled, 
between subjects design  
A single 520 mg isoflavone ↓ 
EtOH binge intake  Penetar et al., 2015 
10 withheld – – – – 
11 withheld – – – – 
Note: *Spoxazomicin D related (cytoprotective against EtOH in OHSC; Shaaban et al., 2017); ┼ Oxachelin C related (cytoprotective against EtOH in OHSC; 
Shaaban et al., 2017); SD = Sprague Dawley strain of rat; EWD = EtOH-withdrawal. Studies presented utilized isoflavonoid compounds isolated from various 





Figure 2.1. Adapted from Zhang et al., 2017. Chemical structures of novel compounds analogs with structural modifications from 
parental compounds indicated. *synthesis compounds are not purified from natural source but rather the total synthesis of the natural 
























 2.3.3. Measurement of Cytotoxicity via Propidium Iodide Staining 
In all experiments, culture medium received the addition of propidium iodide (PI; 
7.48 μM) during the 48 h exposure. PI allows for the quantification of cell death as it can 
only enter cells with disrupted plasma membranes, reflecting the presence of necrotic or 
end-stage apoptotic cells (for a review, see Zimmer et al., 2000). Once inside of the cell, 
PI binds with nucleic acids and produces a red fluorescence in the range of 515-560 nm 
when excited by light. The more compromised cells that are present, the more intense the 
fluorescence will be. Measurement of cytoxicity with PI has been well validated, with PI 
uptake being highly correlated with other markers of cellular viability (e.g., NeuN, 
GFAP, BrdU) in vitro (Wilkins et al., 2006). At 48 h, PI fluorescence was visualized with 
SPOT advanced version 4.0.2 software for Windows (W. Nuhsbahm Inc.; McHenry, IL, 
USA) using a 5x objective with a Leica DMIRB microscope (w. Nuhsbahm Inc.; 
McHenry, IL, USA) fitted for fluorescence detection (mercury-arc lamp) and connected 
to a computer  via a SPOT 7.2 color mosaic camera (W. Nuhsburg). Densitometry using 
Image J software (National Institutes of Health, Bethesda, MD) was used to measure the 
intensity of the PI fluorescence within the entire hippocampal slice. A background 
measurement of fluorescence was taken from the visual field surrounding each slice and 
was subsequently subtracted from the measurement of each slice before analysis. To 
control for the variability between each screen, measurement of PI fluorescence from 
each experiment was normalized to percentage of control using the following formula: 
(S-B)/C, where S is the intensity of fluorescence for a given slice, B is the background 
intensity for that slice, and C is the mean fluorescence for a particular control slice (after 
Mulholland et al., 2005). 
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 2.3.4. Statistical Analysis 
Statistical analyses were conducted to assess the effect of each compound analog 
against EtOH-induced cytotoxicity. As each compound was provided in limited quantity 
by the CPRI, each cytotoxicity screen was performed only 1 time, consistent with our 
prior work (Wang et al., 2015; Shaaban et al, 2017). Notably, a post-hoc power analysis, 
based on the results of our natural product screens (effect size = 2.49; Cohen, 1988), 
suggest 8 slices per group is sufficient to detect a significant difference between EtOH 
(100 mM) and CTRL PI uptake at 48 h using an independent sample t-test with 80% 
power, α = 0.05 (2-tailed test; Gpower; Faul & Erfelder, 1992) (Shaaban et al., 2017). As 
screens were performed over several months, compounds were screened using tissue 
obtained from different rat litters. Data from each screen were converted into percent 
control values (described in Statistical Analysis), yielding a total of 8-9 slices per 
treatment group (EtOH treatment × compound concentration). Data generated from the 
above method was analyzed using a 2-factor ANOVA (EtOH treatment × compound 
concentration), conducted in Prism 5.0 (Graph Pad Software Inc., San Diego, CA, USA). 
The effect of sex was not assessed as prior studies using this model have not identified 
any significant sex differences (Saunders, 2016). When appropriate, post-hoc tests were 
conducted using Tukey.  The level of significance was set at p < 0.05.  
 
2.4. Results 
Studies were conducted to examine novel analog compounds (0.01-1.0 µM) for 
their ability to protect against EtOH (100mM)-induced cytotoxicity in OHSC, as 
determined by uptake of PI at 48 h. The effects of analogs on EtOH-naïve treated 
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 hippocampal explants were also examined. For statistical analyses, a 2-factor ANOVA 
was conducted (EtOH treatment x compound concentration) to establish any 
concentration-response relationships in compound treated tissue. Consistent with 
previous data (Wang et al., 2015; Shaaban et al., 2016), Tukey posttests revealed mean 
increases of PI uptake of approximately 160% of EtOH-naïve controls for EtOH-treated 
tissue, in every experiment (p < 0.05). Following the analog screen, 9 compound analogs 
were identified which significantly attenuated EtOH-induced cytotoxicity (compounds 
2a, 4a, 5a, 6, 7, 9b, 9d, 10, 11). Two-way ANOVA results for each of these compounds 
are summarized in Table 2.2. A significant EtOH treatment x compound concentration 
interaction was revealed for all compounds (p < 0.05), except compound 11 (p = 0.07). 
This suggests that for most compounds, the effect of EtOH treatment on cytotoxicity is 
dependent on the concentration of the compound analog. Post hoc analyses revealed co-
exposure of 2a significantly attenuated EtOH-induced PI-uptake at 0.01 and 0.10 μM (p 
< 0.05). Compound 2a had no significant cytotoxic-effects in CTRL cultures (Figure 
2.3). Compound 4a co-exposure significantly attenuated EtOH-induced PI-uptake at all 
concentrations tested (0.01-1.0 μM) (p < 0.05). However, 4a was found to have 
significant cytotoxic-effects in CTRL cultures at 1 μM (p < 0.05) (Figure 2.4). 
Compound 5a co-exposure also significantly attenuated EtOH-induced PI-uptake at all at 
all concentrations tested (0.01-1.0 μM) (p < 0.05). Compound 5a had no significant 
cytotoxic-effects in CTRL cultures (Figure 2.5). Compound 6 co-exposure significantly 
attenuated EtOH-induced PI-uptake at 0.01 μM (p < 0.05), and was cytotoxic in CTRL 
cultures at both other concentrations (0.10 and 1.0 μM) (Figure 2.6). Compound 7 co-
exposure significantly attenuated EtOH-induced PI-uptake only at the highest (1.0 µM) 
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 concentration tested (p < 0.05). In contrast, 7 was cytotoxic at all concentrations except 
the lowest tested (0.01 µM) in CTRL cultures (Figure 2.7). Compound 9b co-exposure 
significantly attenuated EtOH-induced PI-uptake at the 0.01 and 0.1 μM concentrations 
(p < 0.05). Additionally, 9b was found to have significant cytotoxic-effects in CTRL 
cultures at 1 μM (p < 0.05) (Figure 2.8). Compound 9d co-exposure significantly 
attenuated EtOH-induced PI-uptake at all concentrations tested (0.01- 0.1 μM) (p < 0.05), 
and had no cytotoxic-effects in CTRL cultures (Figure 2.9). Compound 10 co-exposure 
significantly attenuated EtOH-induced PI-uptake at all concentrations tested (0.01-1.0 
μM) (p < 0.05). In CTRL cultures, co-exposure to 10 did reveal significant cytotoxic-
effects at 0.01 μM (p < 0.05) (Figure 2.10). Finally, compound 11 co-exposure 
significantly attenuated EtOH-induced PI-uptake at the 0.10 and 1.0 μM concentrations 
(p < 0.05); notably, both of these groups were still toxic when compared to the EtOH-
naïve CTRL (p < 0.05). In CTRL cultures, co-exposure to 11 revealed significant 










 Table 2.2. Summary of ANOVA results of analog compound effects on propidium iodide 
uptake measured in ethanol (EtOH) and control-treated organotypic hippocampal slice 
cultures.  
Compound Main Effects Interaction [F3, 56 (p)] 
EtOH Treatment [F1, 56 (p)] Concentration [F3, 56 (p)] 
2a 5.83 (0.02) 14.22 (0.0001) 13.46 (0.0001) 
4a 2.05 (0.16) 1.35 (0.27) 6.39 (0.001) 
5a 9.40 (0.003) 7.11 (0.001) 4.70 (0.005) 
6 12.64 (0.001) 4.58 (0.006)  3.24 (0.03) 
7 5.67 (0.02) 2.65 (0.06) 10.30 (0.0001) 
9b 0.14 (0.71) 3.05 (0.04) 5.04 (0.004) 
9d 0.08 (0.77) 4.41 (0.008) 8.08 (0.0001) 
10 0.00 (0.95) 1.04 (0.38) 6.74 (0.0006) 
11 13.84 (0.0005)  0.33 (0.80) 2.48 (0.07)  






























Figure 2.3. (A) Effects compound 2a on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 2a demonstrated no cytotoxic effects in CTRL cultures at 48 h. 
Exposure to 100 mM EtOH for 48 h resulted in significant increases of PI uptake 
compared to CTRL values within hippocampus. This increase was attenuated by the co-
exposure to 0.01 and 0.10 µM of compound 2a.  * = p < 0.05 vs CTRL; ** = p < 0.05 vs 
EtOH, n = 8. (B) Representative images of the effects of 48 h exposure to EtOH (100 



















Figure 2.4. (A) Effects compound 4a on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 4a demonstrated cytotoxic effects in CTRL cultures at the 1 µM 
concentration at 48 h. Exposure to 100 mM EtOH for 48 h resulted in significant 
increases of PI uptake compared to CTRL values within hippocampus. This increase was 
attenuated by co-exposure to all concentrations (0.01-1.0 µM) of 4a.  * = p < 0.05 vs 
CTRL; ** = p < 0.05 vs EtOH, n = 8. (B) Representative images of the effects of 48 h 



















Figure 2.5. (A) Effects compound 5a on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DSMO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 5a demonstrated no cytotoxic effects in CTRL cultures at 48 h. 
Exposure to 100 mM EtOH for 48 h resulted in significant increases of PI uptake 
compared to CTRL values within hippocampus. This increase was attenuated by co-
exposure to all concentrations (0.01-1.0 µM) of 5a.  * = p < 0.05 vs CTRL; ** = p < 0.05 
vs EtOH, n = 8. (B) Representative images of the effects of 48 h exposure to EtOH (100 



















Figure 2.6. (A) Effects compound 6 on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 6 demonstrated cytotoxic effects in CTRL cultures at both the 0.10 
and 1.0 µM concentrations at 48 h. Exposure to 100 mM EtOH for 48 h resulted in 
significant increases of PI uptake compared to CTRL values within hippocampus. This 
increase was attenuated by co-exposure to 0.01 µM of 6.  * = p < 0.05 vs CTRL; ** = p < 
0.05 vs EtOH, n = 8. (B) Representative images of the effects of 48 h exposure to EtOH 



















Figure 2.7. (A) Effects compound 7 on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 7 demonstrated cytotoxic effects in CTRL cultures at both the 0.10 
and 1.0 µM concentrations at 48 h. Exposure to 100 mM EtOH for 48 h resulted in 
significant increases of PI uptake compared to CTRL values within hippocampus. This 
increase was attenuated by the co-exposure to highest (1.0 µM) concentration of 7.  * = p 
< 0.05 vs CTRL; ** = p < 0.05 vs EtOH, n = 8. (B) Representative images of the effects 



















Figure 2.8. (A) Effects compound 9b on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 9b demonstrated cytotoxic effects in CTRL cultures at the 1.0 µM 
concentration at 48 h. Exposure to 100 mM EtOH for 48 h resulted in significant 
increases of PI uptake compared to CTRL values within hippocampus. This increase was 
attenuated by co-exposure to 0.01 and 0.10 µM of 9b.  * = p < 0.05 vs CTRL; ** = p < 
0.05 vs EtOH, n = 8. (B) Representative images of the effects of 48 h exposure to EtOH 



















Figure 2.9. (A) Effects compound 9d on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 9d demonstrated no cytotoxic effects in CTRL cultures at 48 h. 
Exposure to 100 mM EtOH for 48 h resulted in significant increases of PI uptake 
compared to CTRL values within hippocampus. This increase was attenuated by co-
exposure to all concentrations (0.01-1.0 µM) of 9d.  * = p < 0.05 vs CTRL; ** = p < 0.05 
vs EtOH, n = 8. (B) Representative images of the effects of 48 h exposure to EtOH (100 



















Figure 2.10. (A) Effects compound 10 on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 10 demonstrated cytotoxic effects in CTRL cultures at the lowest 
(0.01 µM) concentration at 48 h. Exposure to 100 mM EtOH for 48 h resulted in 
significant increases of PI uptake compared to CTRL values within hippocampus. This 
increase was attenuated by co-exposure to 10 at all concentrations (0.01-1.0 µM).  * = p < 
0.05 vs CTRL; ** = p < 0.05 vs EtOH, n = 8. (B) Representative images of the effects of 



















Figure 2.11. (A) Effects compound 11 on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100) mM treated organotypic hippocampal slices 
cultures. Compound 11 demonstrated cytotoxic effects in CTRL cultures at the 0.01 µM 
concentration at 48 h. Exposure to 100 mM EtOH for 48 h resulted in significant 
increases of PI uptake compared to CTRL values within hippocampus. This increase was 
attenuated by co-exposure to 0.10 and 1.0 µM of 11.  * = p < 0.05 vs CTRL; ** = p < 
0.05 vs EtOH, n = 8. (B) Representative images of the effects of 48 h exposure to EtOH 




CTRL                           EtOH                            11 (0.01µM)                 11 (1.0µM) 
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 2.5. Discussion  
Both clinical and pre-clinical studies have demonstrated that excessive EtOH 
exposure can predict worse neurological outcomes, and that the development of 
neurobiological deficits due to EtOH may serve to drive the development of AUD or 
worsen its existing condition (Koob & Le Moal, 1997). Thus, addressing the underlying 
neurobiological deficits induced by AUD may be an essential feature for an effective 
pharmacotherapy (Van Skike et al., 2016). Natural product compounds represent an 
untapped resource in drug R & D for AUD, as the complex chiral structures observed 
with natural product compounds may provide an enhanced fit to receptors and other 
target proteins (Mentel et al., 2009). Additionally, approximately 60% of drugs on the 
market are directly or indirectly derived from natural product sources (Newman, 2008), 
as natural product screens are associated with a higher hit rate than screens of synthetic 
product libraries. Specifically, HTS of natural product libraries presents with an average 
0.3% hit rate vs 0.001% observed with synthetic compound libraries (Tegos & 
Mylonakis, 2012). In collaboration with scientists at the University of Kentucky Center 
for Pharmaceutical Research and Innovation (CPRI), our lab previously screened several 
compounds from the CPRI natural products repository for their ability to attenuate 48 h 
EtOH (100 mM)-induced increases in propidium iodide (PI) uptake in a rat OHSC model 
(Wang et al., 2015; Shaaban et al., 2017; Zhang et al., 2017). As the creation of natural 
product compound analogs can further increase potency and/or efficacy (Kerns & Di, 
2003), the purpose of the present study was to screen novel analogs of previously 
identified natural product compounds for their ability to attenuate binge-like EtOH-
induced hippocampal cytotoxicity in vitro. 
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 The hypothesis for the current studies was that analogs of natural products 
previously shown to attenuate EtOH-induced neurodegeneration or neurobehavioral 
deficits would attenuate EtOH-induced cytotoxicity with enhanced potency and/or 
efficacy over their parental compound structures. Our results partially supported our 
hypothesis, as 9 of the 20 analogs tested were cytoprotective our screens. Interestingly, 
all hit compound analogs which can be discussed structurally (due to IP limitations, see 
Method) came from 3 parent structure families: oxazole carboxamide (spoxazomicin C 
and N-salicyloyl-2-aminopropan-1-ol), oxachelin, or isoflavonoid. Both oxazole 
carboxamide and oxachelin structures were isolated from Streptomyces sp. RM-14-6, an 
extremophile bacteria isolate from the underground Ruth Mullins coal mine (Shaaban et 
al., 2017). Specifically, compound 2a is an analog of spoxazomicin C, which previously 
did not show cytoprotection in our model (Shaaban et al., 2017; Zhang et al., 2017). 
Compound 4a is not a true analog, but rather the R-enantiomer of N-salicyloyl-2-
aminopropan-1-ol, which is chiral in structure (Zhang et al., 2017). As mentioned 
previously, chiral structures are asymmetric. Due to this, the compound can exist in 
different configurations based on planes of symmetry, which chemists denote as the 
“right hand” (R) and left hand (S)-enantiomer (Cahn, Ingold, & Prelog, 1966). 
Compound 4b was the S-enantiomer, which demonstrated no cytoprotective effects in our 
model. This finding is interesting as the effects of drugs such as baclofen 
(Lorrai, Maccioni, Gessa, & Colombo, 2016), bPiDI (Maggio et al., 2018), and modafinil 
(Maggio et al., 2018) on EtOH self-administration in rats has been shown to be 
enantiomer dependent, specifically showing greater efficacy with the R-enantiomer. 
Notably, both of these compounds are structurally related to spoxazomicin D, which 
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 previously demonstrated potent neuroprotective effects in our model (Shaaban et al., 
2017), but was advanced to in vivo screening for EtOH self-administration in alcohol 
preferring (P) rats and had no effect on drinking behavior (unpublished data). 
Unfortunately, spoxamicin D is a novel isolate (Shaaban et al., 2017), and very little is 
known about the therapeutic targets of related spoxazomicins A-C, beyond their anti-
parasitic effects (Inahashi et al., 2011).  
Also isolated from Streptomyces sp. RM-14-6, oxachelin previously demonstrated 
no cytoprotective effects in our model. However, the oxachelin analog, compound 5a, 
was cytoprotective against EtOH-induced cytotoxicity at all concentrations tested 
(Shaaban et al., 2017; Zhang et al., 2017). A related compound, oxachelin C, did 
demonstrate potent cytoprotective effects against EtOH-induced neurotoxicity in our 
model (Shaaban et al., 2017); however, it did not pass in silico BBB screens, suggesting 
oxachelin C would not be successful at prevention EtOH-induced neurobiological or 
neurobehavioral effects in vivo. Oxachelin is known to chelate (i.e., bind and remove) 
iron (Sontag et al., 2006), and pathological accumulation of iron in the brain is a hallmark 
of nearly all neurodegenerative diseases (Dusek, Schneider, & Aaseth, 2016). Indeed, a 
positive-feedback relationship between oxidative stress, neuroimmune signaling, iron 
accumulation, and neurotoxicity has been proposed (Urrutia, Mena, & Núñez, 2014). 
Thus, future studies should evaluate whether compound 5a may exert its neuroprotective 
effects through its action on iron levels.  
While we have not previously screened isoflavonoid compounds in our lab, prior 
research has found that administration of isoflavonoids isolated from the kudzu plant 
(e.g., puerarin, daidzin, daidzein [DZ]) reduce EtOH intake in both rodents (Lin & Li, 
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 1998; Benlhabib, Baker, Keyler & Singh, 2004) and humans (Lukas et al., 2005; 2013; 
Penetar et al., 2012; Penetar, Toto, Lee, & Lukas, 2015). The ability of isoflavonoids to 
reduce the in vitro excitotoxic effects (Lutz et al., 2015a) and in vivo anxiogenic effects 
of EtOH withdrawal has also been observed (Overstreet et al., 2003; Benlhabib et al., 
2004). However, the effect of these compounds on EtOH-exposure induced neurotoxicity 
has not been explored. Isoflavonoid analog compounds 9b and 9d both demonstrated 
potent cytoprotective effects in our model. Notably, isoflavonoids are reported to exert a 
myriad of effects within the CNS (e.g., estrogen receptor binding, anti-inflammatory, 
antioxidant, cytoprotective) (Miadoková, 2009; Wozniak, Janda, Kapusta, Oleszek, & 
Matkowski 2010; Sakran, Selim, & Zidan, 2014; Aras et al., 2015). Interestingly, 4 
structurally-related compounds (9a, 9c, 9e, 9f) did not exert cytoprotection in our model. 
As all compounds retained a similar composition of hydroxyl (OH) groups in Ring B at 
both R3′ and R5′, and these structural substitutions from the basic common isoflavonoid 
structure modulate different isoflavonoid antioxidant effects (Promden, Monthakantirat, 
Umehara, Noguchi, & De-Eknamkul, 2014), compound 9b and 9d likely exert their 
cytoprotective effects in our model via another mechanism. Interestingly, compound 9b 
and 9d only diverges structurally from the other analogs via their R8 (ring A) and R4’ 
(ring B) substitution pattern (Figure 2.1). Compound 9b and 9d both share the addition of 
fluorine at R4′, and fluorinated natural products have been shown to increase metabolic 
stability, binding affinity, lowering of surface tension, hydrophobicity, and lipophobicity 
(for a review, see Monsen & Luzzio, 2017). However, 9b and 9d differ in that compound 
9b contains the addition of a piperidine at R8 (9d has a hydrogen at this position). While 
9e also has this piperidine, but shows no cytoprotection (but it lacks a fluorine), it is still 
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 interesting as piperidine is conserved in lobeline, and sigma-1 receptor (σ1R) antagonists; 
and lobeline and σ1R antagonists have been shown to reduce EtOH consumption in 
rodents in vivo (Bell, Eiler II, Cook, & Rahman, 2009; Farook, Lewis, Gaddis, Littleton, 
& Barron, 2009; Sabino et al., 2009). Lobeline primarily acts as an agonist at the 
nicotinic α4β2 subunit, and activity at this receptor has been shown to decrease NF-κB 
and production of the pro-inflammatory cytokines IL-1β and IL-6 in SHEP1-hα4β2 cells 
(Hosur & Loring, 2010). A study by Yao and colleagues (2010) has also demonstrated 
that administration of σ1R antagonists inhibits activation of NF-κB pathways in BV2 
microglia cultures. Furthermore, our lab has demonstrated that σ1R antagonists are 
protective against CIE-induced neurotoxicity in OHSC (Reynolds et al., 2016).  These 
data suggests that isoflavonoids such as 9b and 9d have potential for the use in reducing 
EtOH-induced neurotoxicity, as well as an important structure-activity relationship 
between fluorine and piperidine in our model.  
Interestingly, while both oxachelin and spoxazomicin C did not pass in silico 
BBB screens prior to cytotoxicity testing in our prior studies (Shaaban et al., 2017), both 
analog compounds 2a and 5a did pass these screens (Zhang et al., 2017). Furthermore, 
both compound 2a and 5a were structurally modified only via glycosylation (the addition 
of a sugar). Glycosylation of natural product compounds has been previously employed 
to improve drug potency, mechanism, pharmacodynamic, pharmacokinetic, and ADME 
properties (Gantt, Peltier-Pain, & Thorson, 2011; Goff & Thorson, 2012; Zhang et al., 
2017). However, the current structure-activity relationships also suggest an impact of 
glycosylation on improving BBB permeability (Egleton et al., 2001; Fichna et al., 2013), 
which may support future lead optimization studies for compounds intended for the 
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 treatment of neurological deficits due to AUD (Wang et al., 2015; Shaaban et al., 2017; 
Zhang et al., 2017).  
However, a limitation of this study is that CPRI-withholding of parental and analog 
structures for several hit compounds (1, 6, 7, 10, and 11) to preserve I.P. limits the 
interpretation of several findings, as well as any decision making towards lead compound 
advancement. Additionally, each compound was only screened a single time. This is 
normal practice in initial stage HTS, as testing and replication of very large chemical 
libraries is burdensome; however, there is the possibility of a false positive or a false 
negative result (Kelly, 2009). Furthermore, while significant attenuation of EtOH-
induced cytotoxicity by the potent antioxidant Trolox has been observed in the current 
model, and may suggest EtOH exerts its neurodegenerative effects via oxidative stress, 
no additional markers (e.g., neuroimmune mediators, proteases, NMDAR activation) 
have been assessed to firmly characterize the mechanism of cytotoxicity within our 
model (Saunders, 2016). Furthermore, while PI has been correlated with other markers of 
cell death (Wilkins et al., 2006), analysis of this marker is time dependent, presenting the 
opportunity for user error. Even though they are more time consuming, employment of 
specific and reliable markers, such as the neuron-specific marker NeuN (Kim, Adelstein, 
& Kawamoto, 2009), may help elucidate specific effects of compounds on certain cell 
types (neurons vs glia), as well as serve to better verify findings of cell death, before 
advancing a compound into further screening phases.  
While the findings from the current study should be interpreted as preliminary, they 
suggest important structure-activity relationships that may support future target 
identification (e.g., via incorporation of sugars, fluorine, or piperidine), and given the 
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 impact of glycosylation on improving BBB permeability (Egleton et al., 2001; Fichna et 
al., 2013), may also aid in informing optimization studies in the context of advancing 
lead compounds for the treatment of the neurological deficits resulting from AUD (Wang 
et al., 2015; Shaaban et al., 2017; Zhang et al., 2017). Future research should be 
conducted to characterize the mechanism by which the 9 lead compounds identified here 
(2a, 4a, 5a, 6, 7, 9b, 9d, 10, 11) exert their cytoprotective effects to further explore the 
potential of these novel compound analogs as potential treatment options in reducing the 

















 CHAPTER THREE: Study Two: Effect of a Novel Isoflavonoid Analog on Binge 
Ethanol-Induced Neuroimmune Signaling In Vitro 
3.1. Introduction  
There is significant difficulty in developing a successful treatment for AUD, as 
EtOH does not act at 1 specific target, but rather causes neurotoxicity through several 
mechanisms, including activation of pro-inflammatory neuroimmune cascades (Blanco et 
al., 2005; Fernandez-Lizarbe et al., 2009; Alfonso-Loeches et al., 2010; Pascual et al., 
2011) and excitotoxicity (Lovinger, 1993; Davis & Wu, 2001; Nagy & Laszlo, 2002; 
Prendergast et al., 2004). While EtOH-induced excitotoxicity primarily involves 
interactions with the glutamatergic NMDAR (Lovinger, 1993; Tsai, 1998; Wirkner et al., 
1999; Davis & Wu, 2001; Nagy & Laszlo, 2002; Ron, 2004), several reports suggests that 
these interactions may be secondary to the induction of persistent neuroimmune 
activation (for a review, see Crews et al., 2015); therefore, therapeutic strategies which 
address this mechanism could be effective at ameliorating the toxicity of both 
pathologies. Increased markers for the pro-inflammatory transcription factor, nuclear 
factor kappa-light-chain-enhancers of activated B cells (NF-κB) (Liu et al., 2006; Okvist 
et al., 2007) and upregulated neuroimmune gene expression have also been observed (He 
and Crews, 2008). In pre-clinical studies, activation of a second pro-inflammatory 
transcription factor, activator protein 1 (AP-1), has also been observed in response to 
EtOH (Fried et al., 2001; Blanco, et al., 2005). Both NF-κB and AP-1 are known to 
increase the expression of cytokines (TNF-a, IL-1β, IL-6, MCP-1), and these effects are 
associated with inflammation and cell death (for a review, see Blanco and Guerri, 2006).  
Alfonso-Loeches and colleagues (2010) found that activation of NF-κB in response to 
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 chronic EtOH exposure was associated with increased levels of IL-1β, TNF-α, IL-6, and 
several oxidases (e.g.,  COX-2 and iNOS) in the cerebral cortex of female wide-type 
mice. This increase in COX-2 and iNOS by NF-κB could lead to oxidative stress through 
the generation of ROS (Sun et al., 2001). As ROS can directly activate NF-κB, oxidative 
stress may also contribute to the persistent innate immune response observed following 
chronic EtOH consumption (for a review, see Crews et al., 2013).  
While several mechanisms may be involved in the upstream signaling which 
results in NF-κB transcription, evidence suggests EtOH-induced activation of NF-κB is 
dependent on signaling through toll-like receptors (TLRs). In the previously mentioned 
study by Alfonso-Loeches and colleagues (2010), knockdown of TLR4 abolished the 
activation of NF-κB pathways and induction of inflammatory mediators in primary 
astrocyte cultures. The TLR pathway is highly conserved in rodents and humans and 
represents the canonical mechanism of NF-κB activation (Hoesel & Schmid, 2013). 
Protein expression for several TLRs (i.e. TLR2, TLR3, TLR4) and high-mobility group 
box 1 (HMGB1), an endogenous danger signaling cytokine and TLR4 agonist, is 
upregulated following chronic EtOH exposure in mice, rat brain slice cultures, and the 
post-mortem brains of alcoholics (Crews et al., 2013). HMGB1 is known to stimulate 
TLR4 and lead to the production of ROS and downstream activation of NF-κB (for a 
review, see Tang et al., 2011). HMGB1 has also been shown to induce ROS and NF-κB 
activation via action at the receptor for advanced glycation end-products (RAGE), 
although the role of this receptor in EtOH-induced neuroinflammation is less clear (Tang, 
et al., 2011; Crews et al., 2015). Notably, brain slice cultures do show that EtOH-induces 
signaling through HMGB1-TLR4, resulting in IL-1β release; further, neutralizing 
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 antibodies to HMGB1 or siRNAs against HMGB1-TLR4 attenuate this EtOH-dependent 
induction of IL-1β (Crews et al., 2013).  Ultimately, this upregulation in pro-
inflammatory mediators has been associated with an increased expression of “pro death 
signals” (e.g., caspase 3 and calpain) and apoptotic cell death (Vallés et al., 2004; Zhao et 
al., 2015). However, apoptosis is not observed in EtOH-exposed microglia and astroglia 
deficient in TLR4 or in TLR4 knockout mice (Blanco et al., 2005; Fernandez-Lizarbe et 
al., 2009; Alfonso-Loeches et al., 2010; Pascual et al., 2011). This suggests a direct role 
of TLR4-dependent neuroimmune signaling in the promotion EtOH-induced 
neurotoxicity. Furthermore, TLR4 knockout mice exhibit less EtOH-induced cognitive 
and motor impairments than wild type mice (Pascual et al., 2011) and reduced self-
administration of EtOH is observed in alcohol preferring (P) rats following amygdala-
specific TLR4 inhibition (Liu et al., 2011). 
 
3.2. Experimental Rationale  
These studies suggest a role for HMGB1-TLR4 in EtOH-induced excitotoxicity, 
neurodegeneration, and behavioral deficits. Isoflavonoids are polyphenolic compounds 
which can be found in several legumes (soy, peanuts, chick peas) (Barnes, 2010). 
Isoflavonoids readily distribute to all tissues, including the brain (Chandrasekharan & 
Aglin, 2013), and are known influence several processes within CNS, including estrogen 
receptor binding, neuroimmune signaling, intracellular redox status, and to have 
antioxidant and cytoprotective properties (Miadoková, 2009; Wozniak et al., 2010; 
Sakran et al., 2014; Aras et al., 2015; Subedi et al., 2017). Additionally, prior research 
has found that the administration of isoflavonoids (e.g., puerarin, daidzin, daidzein [DZ]) 
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 reduces EtOH intake in both rodents (Lin & Li, 1998; Benlhabib et al., 2004) and humans 
(Lukas et al., 2005; 2013; Penetar et al., 2012; 2015). The ability of isoflavonoids to 
reduce the in vitro cytotoxic (Lutz et al., 2015a) and in vivo anxiogenic effects of EtOH 
withdrawal has also been observed (Overstreet et al., 2003; Benlhabib et al., 2004). 
Although the precise mechanism by which isoflavonoids attenuate consumption is not yet 
known, the anti-inflammatory capacity of these compounds may underlie their protective 
properties. Isoflavonoids have been shown to directly scavenge reactive oxygen, 
nitrogen, and chlorine species (Boersma et al., 1999; Patel et al., 2001). Moreover, oral 
administration of the isoflavonoids genistein and DZ decreased serum RNS levels in 
LPS-challenged rats (Yen & Lai, 2003), suggesting that isoflavonoids scavenge increased 
free radicals produced during inflammation and may prevent persistent neuroimmune 
activation and resultant cell damage. However, independent of their antioxidant effects, 
isoflavonoids have been shown to modulate neuroimmune signaling through upstream 
regulation of the DNA-binding capacity of both NF-κB and AP-1 (Park et al., 2007; 
Chinta, Ganesan, Reis-Rodrigues, Lithgow, & Andersen, 2013) and inhibition of the 
production of cytokines and chemokines such as IL-1β, IL-6, IL-12, and TNF-α in 
diverse models of inflammation in vitro (Morimoto, Watanabe, Yamori, Takebe, & 
Wakatsuki, 2009; Ji et al., 2012; Gao et al., 2014; Lutz et al., 2015a), in vivo (Paradkar 
Blum, Berhow, Baumann, & Kuo, 2004; Ganai, Khan, Malik, & Farooqi, 2015), and in 
humans (Lesinski et al., 2015). Furthermore, the inhibitory effect of DZ on IL-6 and IL-8 
in monocytes may be mediated through its action at the TLR2 and TLR4 receptors 
(Morimoto et al., 2009). In a recent study, Subedi and colleagues (2017) found that 
equol, a DZ gut metabolite, inhibited LPS-induced TLR4 activation, MAPK activation, 
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 NF-kB-mediated transcription of inflammatory mediators, NO production, and 
secretion of TNF-α and IL-6 from murine microglia cells. A downregulation of 
neuronal apoptosis was also observed in LPS-treated N2a cells co-exposed to equol 
(Subedi et al., 2017).  
In Study 1 we identified a novel isoflavonoid analog which attenuated 48 h binge 
EtOH-induced cytotoxicity at 0.01 and 0.10 µM (the lowest concentrations tested). 
Further, 4 structurally-related compounds (9a, 9c, 9e, 9f) did not demonstrate this 
efficacy in our model. As all compounds retained a similar composition of hydroxyl (OH) 
groups in Ring B at both R3′ and R5′, and these structural substitutions from the basic 
common isoflavonoid structure modulate different isoflavonoid antioxidant effects 
(Promden et al., 2014), compound 9b likely exerts its cytoprotective effects in our model 
via another mechanism. Compound 9b only diverges structurally via its R8 (ring A) and 
R4’ (ring B) substitution pattern (Study 1, Figure 2.1). Notably, the addition of fluorine at 
R4′ is interesting, as fluorinated natural products display beneficial biological properties, 
such as increased metabolic stability, binding affinity, lowering of surface tension, 
hydrophobicity, and lipophobicity (for a review, see Monsen & Luzzio, 2017). The 
addition of a piperidine at R8, while not unique to compound 9b, is also interesting as it 
conserved in lobeline, and σ-1 receptor (σ1R) antagonists; and lobeline and σ1R 
antagonists have been shown to reduce EtOH consumption in rodents in vivo (Bell et al., 
2009; Farook et al., 2009; Sabino et al., 2009). Lobeline primarily acts as an agonist at 
the nicotinic α4β2 subunit, and activity at this receptor has been shown to decrease NF-
κB and production of the pro-inflammatory cytokines IL-1β and IL-6 in SHEP1-hα4β2 
cells (Hosur & Loring, 2010). A study by Yao and colleagues (2010) has also 
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 demonstrated that administration of σ1R antagonists inhibits activation of NF-κB 
pathways in BV2 microglia cultures. Furthermore, our lab has demonstrated that σ1R 
antagonists are protective against CIE-induced neurotoxicity in OHSC (Reynolds et al., 
2016).   
Previous studies have used the OHSC model for the examination of EtOH-
induced neurodegeneration (Collins, Zou, & Neafsey, 1998; Bulter et al., 2013; Reynolds 
et al., 2015a) and neuroimmune signaling (Moon et al., 2014; Lutz et al., 2015a,b). 
OHSCs provide a good model for the examination of EtOH-induced changes on 
neuroimmune signaling as neuron-glia interactions remain intact in this model 
(Benediktsson et al., 2005; Haber et al., 2009; Dailey & Waite, 1999). Therefore, in the 
present study, we evaluated a lower concentration range of compound 9b (0.0001-0.01 
µM) for inhibitory effects on EtOH-induced hippocampal cytotoxicity and altered 
neuroimmune signaling in vitro using the exposure method described in Study 1, to 
establish dose-response relationships. As 9b was cytoprotective at 0.01 µM in Study 1, 
and isoflavonoids have been shown to have dose dependent anti-apoptotic actions down 
to 0.05 µM in a previous study (Adams et al., 2012), we expected 0.01 µM to remain the 
most cytoprotective concentration. As DZ is a prototypical isoflavonoid, and has been 
previously shown to reduce EtOH intake (Lin & Li, 1998; Benlhabib et al., 2004; Lukas 
et al., 2005; 2013; Penetar et al., 2012; 2015) and modulate neuroimmune signaling 
(Morimoto et al., 2009; Subedi et al., 2017), it was used as a comparison compound. 
Based on these previous studies, we hypothesized that co-exposure to DZ would inhibit 
EtOH-induced pro-inflammatory mediator release into medium during a 48 h EtOH 
exposure. Additionally, as 9b exhibited structural similarities to lobeline and σ-1R 
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 antagonist, compounds which have been shown to attenuate neuroimmune signaling 
(Hosur & Loring, 2010; Wu et al., 2015), and were unique from DZ, we hypothesized 
that 9b might have more anti-inflammatory potential than DZ. 
 
3.3. Method 
The following section closely follows methods detailed in Chapter 2. For the reader’s 
convenience, changes and additions have been underlined. 
3.3.1. Organotypic Hippocampal Slice Culture Preparation 
Male and female Sprague-Dawley rat pups (i.e., 8 days old) (Harlan Laboratories; 
Indianapolis, IN) were humanely sacrificed. Whole brains were aseptically removed 
(after Mulholland et al., 2005) and immediately placed into culture dishes containing 
chilled dissecting medium composed of Minimum Essential Medium (MEM; Invitrogen, 
Carlsbad, CA), 25 mM HEPES (Sigma, St. Louis, MO), 21.20 µM Amphotericin B 
solution (Sigma), and 50 µM streptomycin/penicillin (Invitrogen). Bilateral hippocampi 
were removed and placed into culture dishes containing chilled culture medium 
composed of dissecting medium, double distilled water, 36 mM glucose (Fisher, 
Pittsburg, PA), 25% Hanks’ Balanced Salt Solution (HBSS; Invitrogen), 25% (v/v) heat-
inactivated horse serum (HIHS; Sigma), 0.05% Amphotericin B solution (Sigma), and 
0.10% streptomycin/penicillin (Invitrogen). Excess tissue attached to hippocampi was 
carefully removed with the use of a stereoscopic microscope. Each hippocampus was 
then coronally sectioned at 200 µm thickness using a McIllwain Tissue Chopper (Mickle 
Laboratory Engineering Co. Ltd., Gomshall, UK) and transferred to a culture dish 
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 containing chilled culture medium. Hippocampal slices were selected for inclusion of all 
three hippocampal regions (CA1, CA3, and dentate gyrus) through examination under a 
stereoscopic microscope. Following selection, 4 slices were plated onto Millicell-CM 0.4 
µM biopore membrane inserts sitting in 35-mm 6-well culture plates containing 1 mL of 
pre-incubated culture medium. This method produces 24 intact hippocampal slices per 6-
well plate. To allow for air exposure, all excess culture medium was carefully removed 
from the top of each culture well. To allow hippocampal slices to adhere to the biopore 
membrane inserts, the tissue was stored in an incubator at 37°C with a gas composition of 
5% CO2/95% air for 5 days before experiments were conducted. Care of all animals was 
carried out in agreement with the University of Kentucky’s Institutional Animal Care and 
Use Committee.  
 
3.3.2. EtOH and Compound Treatment 
 At 5 days in vitro (DIV), after the hippocampal slices have adhered to the biopore 
membrane, cultures were transferred at random to 6-well culture plates containing 1 mL 
of culture medium with 0.01% DMSO (DMSO vehicle control [CTRL]; Fisher) or 1 mL 
of culture medium with the addition of 0.01% DMSO and 100 mM EtOH.  Additional 
cultures were exposed to CTRL or EtOH (100 mM) medium with the addition of 
compound 9b or DZ (diluted to 0.01% DMSO as previously describe). As the previous 
study revealed cytoprotective effects at the lowest concentration tested (0.01 µM), a 
lower concentration range (0.0001-0.01 µM) was used in the current study to better 
characterize the effects of this compound. All culture media also received the addition of 
propidium iodide (PI; 7.48 μM) during the 48 h exposure (discussed below in 
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 Measurement of Cytotoxicity via Propidium Iodide Staining). In order to prevent 
diffusion of EtOH from the culture medium, all EtOH treated plates were placed into 
topless polypropylene containers containing 50 mL of ddH2O with the addition of 100 
mM EtOH. CTRL groups received similar treatment, without the addition of (receiving 
EtOH-naïve ddH20). Containers were then placed in sealable 1-gallon freezer bags and 
filled with compressed gas (5% carbon dioxide/95% air), to mimic the incubator 
conditions, and returned to the incubator for 48 h. Attempts were made to prevent 




































 3.3.3. Measurement of Cytotoxicity via Propidium Iodide Staining 
 Similar to Study 1, all cultures received the addition of propidium iodide (PI; 
7.48 μM) during the 48 h exposure. Propidium iodide (PI) allows for the quantification of 
cell death as it can only enter cells with disrupted plasma membranes, reflecting the 
presence of necrotic or end-stage apoptotic cells (for a review, see Zimmer et al., 2000). 
Once inside of the cell, PI binds with nucleic acids and produces a red fluorescence in the 
range of 515-560 nm when excited by light. The more compromised cells that are 
present, the more intense the fluorescence will be. Measurement of cytoxicity with PI has 
been well validated, with PI uptake being highly correlated with other markers of cellular 
viability (e.g. NeuN, GFAP, BrdU) in vitro (Wilkins et al., 2006). At 48 h, PI 
fluorescence was visualized with SPOT advanced version 4.0.2 software for Windows 
(W. Nuhsbahm Inc.; McHenry, IL, USA) using a 5x objective with a Leica DMIRB 
microscope (w. Nuhsbahm Inc.; McHenry, IL, USA) fitted for fluorescence detection 
(mercury-arc lamp) and connected to a computer  via a SPOT 7.2 color mosaic camera 
(W. Nuhsburg). Densitometry using Image J software (National Institutes of Health, 
Bethesda, MD) was used to measure the intensity of the PI fluorescence within the entire 
hippocampal slice. A background measurement of fluorescence was taken from the visual 
field surrounding each slice and was subsequently subtracted from the measurement of 
each slice before analysis. To control for the variability between each screen, 
measurement of PI fluorescence from each replication was normalized to percentage of 
control using the following formula: (S-B)/C, where S is the intensity of fluorescence for 
a given slice, B is the background intensity for that slice, and C is the mean fluorescence 
for a particular control slice (after Mulholland et al., 2005).  
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 3.3.4. ELISA Measurements of HMGB1, TNF-α, IL-6, and IL-10 Release  
Following the assessment of PI uptake in hippocampal cultures, slices were 
discarded and pooled culture media was collected for use in Enzyme-Linked 
Immunosorbent Assay (ELISA). Sample media were stored at -80°C until use. Previous 
studies have found that binge EtOH exposure increases TNF-α mRNA and induces 
release of HMGB1 into hippocampal-entorhinal (HEC) slice culture medium (Crews et 
al., 2013; Coleman, Zou, & Crews, 2017). In vivo studies also suggest a role for IL-6 in 
EtOH-induced neurological and neurobehavioral deficits (Heberlein et al., 2014; Zago et 
al., 2016 Casachahua, 2016). Thus, the presence of released HMGB1 (NeoBioLab, 
#RH0016), TNF-α (Invitrogen, #KRC3011C), and IL-6 (R & D Systems kit, #R6000B) 
was determined via ELISA according to the manufacturer’s instructions. HMGB1 can 
lead to the initiation of pro- and anti-inflammatory cascades dependent on its redox state 
(Venereau et al., 2012), thus, levels of the prototypical anti-inflammatory cytokine IL-10 
(Invitrogen, #KRC0101) were also assessed. While no direct model translation has been 
characterized in hippocampal slice cultures, Lutz et al. (2015a,b) found that exposure of 
hippocampal slice cultures to LPS (10 ug/mL) produced increases in TNF-α release into 
culture medium at 24 h that persisted through hour 72. As LPS has been demonstrated to 
induce all of our neuroimmune mediators of interest, LPS (10 ug/mL; Lutz et al., 
2015a,b) was used as a positive control for all assays except IL-6, for which R & D 
systems provided a specific positive control. All standards and samples were run in 
duplicate. Absorbance was measured at 450 nm using a Beckman Coulter DTX 880 
Mulitmodal Detector (Lagerhausstrasse, Austria) with Beckman Coulter Multimode 
Detection Software (v.20.0.12). Mean concentrations of inflammatory mediators for each 
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 sample was determined based upon a standard curve (defined by known samples 
provided by each kit) that was analyzed along with the experimental samples. To control 
for the variability between each screen, cytokine concentrations are reported as percent of 
control. 
 
3.3.5. Statistical Analysis  
Statistical analyses were conducted to assess the inhibitory effect of compound 9b 
and DZ on EtOH-induced cytotoxicity and neuroimmune signaling. Study 2 was 
conducted two times, using two different rat litters. Data from each cytotoxicity screen 
were converted into percent control values, yielding a total 16 slices per treatment group 
(EtOH treatment × compound concentration). Data from each ELISA assay were 
converted into percent control values, yielding a total of three pooled media samples per 
treatment group (EtOH treatment × compound concentration). Data generated from the 
above method was analyzed using a 2-factor ANOVA (EtOH treatment × compound 
concentration), conducted in Prism 5.0 (Graph Pad Software Inc., San Diego, CA, USA). 
Similar to Study 1, the effect of sex was not assessed. When appropriate, post-hoc tests 
were conducted using Tukey.  The level of significance was set at p < 0.05.  
 
3.4. Results  
3.4.1. Co-Exposure to Compound 9b or Daidzein Attenuates PI-Uptake Following 48 h 
EtOH-Exposure 
Studies were conducted to examine the effects of compound 9b (0.0001-0.01 µM) 
for its ability to attenuate EtOH (100mM)-induced cytotoxicity in OHSC, as determined 
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 by uptake of PI at 48 h. DZ (0.0001-0.01 µM), a prototypical isoflavonoid which is 
known to reduce EtOH intake and withdrawal in vivo and in vitro (refer to chapter 
introduction), was used as a comparison compound. The effects of 9b and DZ on EtOH-
naïve treated hippocampal explants were also examined. For statistical analyses, a 2-
factor ANOVA was conducted (EtOH treatment x compound concentration) to establish 
any concentration-response relationships in 9b or DZ treated tissue. Consistent with our 
previous natural product screens (Wang et al., 2015; Shaaban et al., 2017) and Study 1, 
EtOH (100 mM) exposure for 48 h resulted in significant uptake of PI compared to 
CTRL treated cultures for both experiments (p < 0.001). For compound 9b, within the 
hippocampus, a significant main effect of EtOH treatment [F(1,116)=11.32, p < 0.001] 
and compound concentration [F(3,116)=3.56, p < 0.05] was observed. Additionally, a 
significant interaction between EtOH treatment x compound concentration was detected 
in cultures co-exposed to 9b, F(3,116)=6.21, p < 0.001.  Post hoc analyses revealed co-
exposure to 9b significantly attenuated EtOH-induced PI-uptake at 0.001 and 0.10 μM (p 
< 0.05), and had no cytotoxic effects in EtOH-naïve CTRL cultures (Figure 3.2). 
Similarly, for DZ, a significant main effect of EtOH treatment [F(1,120)=4.55, p < 0.05] 
and compound concentration [F(3,120)=4.04, p < 0.01] was observed, as well as a 
significant EtOH treatment x compound concentration interaction, F(3,120)=8.65, p < 
0.0001. Post hoc analyses revealed co-exposure to DZ significantly attenuated EtOH-
induced PI-uptake at all concentrations tested (0.0001-0.10 μM (p < 0.05). Notably, DZ 
was found to have significant cytotoxic-effects in EtOH-naïve CTRL cultures at the 
















Figure 3.2. (A) Effect of compound 9b on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100 mM)-treated organotypic hippocampal slices 
cultures. Compound 9b demonstrated no cytotoxic effects in CTRL cultures at 48 h. 
Exposure to 100 mM EtOH for 48 h resulted in significant increases of PI uptake 
compared to CTRL values within hippocampus. This increase was attenuated by co-
exposure to 0.001 and 0.01 µM of compound 9b.  * = p < 0.05 vs CTRL; ** = p < 0.05 
vs EtOH, n = 15-16. (B) Representative images of the effects of 48 h exposure to EtOH 



















Figure 3.3. (A) Effect of daidzein (DZ) on propidium iodide (PI) uptake at 48 h in EtOH-
naïve DMSO CTRL and EtOH (100 mM)-treated organotypic hippocampal slices 
cultures. DZ demonstrated cytotoxic effects in CTRL cultures at the 0.001 µM 
concentration at 48 h. Exposure to 100 mM EtOH for 48 h resulted in significant 
increases of PI uptake compared to CTRL values within hippocampus. This increase was 
attenuated by the co-exposure to all concentrations (0.0001-0.01 µM) of DZ. * = p < 0.05 
vs CTRL; ** = p < 0.05 vs EtOH, n = 15-16. (B) Representative images of the effects of 





CTRL                           EtOH                            DZ (0.0001µM)            DZ (0.01µM) 
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 3.4.2. Co-Exposure to Compound 9b or Daidzein Attenuates HMGB1 and IL-6 Release 
Following 48 h EtOH-Exposure 
  To investigate whether compound 9b or DZ may exert their effect via modulation 
of neuroimmune mediators, ELISAs were performed on the 48 h culture media for 
HMGB1, TNF-α, IL-6, and IL-10. For statistical analyses, a 2-factor ANOVA was 
conducted (EtOH treatment x compound concentration) to establish any concentration-
response relationships. Initial data cleaning revealed no detectable levels (when 
compared to the ELISA standard curve) of TNF-α or IL-10 in any group except for the 
LPS (10 ug/mL) positive control group. Thus, no statistical analyses were conducted on 
these data. Consistent with previous data indicating and dose-dependent 85% increase in 
HMGB1 release following a 48 h exposure to EtOH (25-100mM) in rat HEC slice 
cultures (Coleman et al., 2017), and IL-6 is increased following EtOH consumption both 
in vivo (Alfonso-Loeches et al., 2010) and in human (Heberlein et al., 2014; Zago et al., 
2016), EtOH (100mM) exposure for 48 h resulted in significantly higher HMGB1 and IL-
6 release into EtOH medium compared to EtOH-naïve CTRL medium (p < 0.05).  For 
compound 9b, analyses on media for HMGB1 release revealed a significant main effect 
of compound concentration, F(3,16)=7.16, p < 0.01. Additionally, a significant 
interaction between EtOH treatment x compound concentration was detected, 
F(3,16)=13.97, p < 0.0001.  Post hoc analyses revealed that co-exposure to 9b 
significantly attenuated EtOH-induced HMGB1 release at all concentrations tested 
(0.0001-0.10 μM) (p < 0.05), and had no effect on HMGB1 release into EtOH-naïve 
CTRL medium (Figure 3.4a). Analyses on media assessing for 9b’s effects on IL-6 
release revealed a significant main effect of EtOH treatment [F(1,16)=5.79, p < 0.05] and 
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 compound concentration [F(3,16)=86.93, p < 0.0001]. Additionally, a significant 
interaction between EtOH treatment x compound concentration was detected, 
F(3,16)=29.77, p < 0.0001.  Post hoc analyses revealed co-exposure to 9b significantly 
attenuated EtOH-induced IL-6 release at all concentrations tested (0.0001- 0.10 μM) (p < 
0.05). Further, this reduction of IL-6 by 9b was to a level below that of both EtOH-naïve 
CTRL and 9b treated EtOH-naïve CTRL media (p < 0.05). Compound 9b co-exposure 
had no significant effect on IL-6 release into CTRL medium when compared to the naïve-
CTRL (Figure 3.5a). For DZ, analyses on media for HMGB1 release revealed a 
significant both a significant main effect of EtOH treatment [F(1,16)=22.67, p < 0.001] 
and compound concentration [F(3,16)=6.30, p < 0.01]. Additionally, a significant 
interaction between EtOH treatment x compound concentration was detected, 
F(3,16)=3.79, p < 0.05.  Post hoc analyses revealed that co-exposure to DZ significantly 
attenuated EtOH-induced HMGB1 release at all concentrations tested (0.0001- 0.10 μM) 
(p < 0.05), and had no effect on HMGB1 release into EtOH-naïve CTRL medium (Figure 
3.4b). Analyses on media assessing for DZ’s effects on IL-6 release revealed a significant 
main effect of EtOH treatment [F(1,16)=383.41, p < 0.0001] and compound 
concentration [(F(3,16)=415.73, p < 0.0001]. Additionally, a significant interaction 
between EtOH treatment x compound concentration was detected, F(3,16)=115.86, p < 
0.0001.  Post hoc analyses revealed co-exposure to DZ significantly attenuated EtOH-
induced IL-6 release at all concentrations tested (0.0001- 0.10 μM) (p < 0.001). Further, 
this reduction of IL-6 by DZ was to a level below that of both EtOH-naïve CTRL and DZ 
treated EtOH-naïve CTRL media (p < 0.001). DZ co-exposure had no effect on IL-6 




Figure 3.4. Effects of compound (A) 9b and (B) daidzein on HMGB1 release into the 
media of EtOH-naïve DMSO CTRL and EtOH (100 mM)-treated organotypic 
hippocampal slices cultures. Exposure to EtOH (100mM) for 48 h resulted in 
significantly higher HMGB1 release into medium compared to CTRL medium. (A) 9b 
significantly attenuated EtOH-induced HMGB1 release into culture medium at all 
concentrations tested (0.0001- 0.10 μM), and had no effects on HMGB1 release into 
CTRL medium. (B) Daidzein significantly attenuated EtOH-induced HMGB1 release 
into culture medium at all concentrations tested (0.0001- 0.10 μM), and had no effects on 
HMGB1 release into CTRL medium. LPS (10 ug/mL) was used as a positive control. * = 














Figure 3.5. Effects of compound (A) 9b and (B) daidzein on IL-6 release into the media 
of EtOH-naïve DMSO CTRL and EtOH (100 mM)-treated organotypic hippocampal 
slices cultures. Exposure to EtOH (100mM) for 48 h resulted in significantly higher IL-6 
release into medium compared to CTRL medium. (A) 9b significantly attenuated EtOH-
induced IL-6 release into culture medium at all concentrations tested (0.0001- 0.10 μM), 
and had no effects on IL-6 release into CTRL medium. (B) Daidzein significantly 
attenuated EtOH-induced IL-6 release into culture medium at all concentrations tested 
(0.0001- 0.10 μM), and had no effects on IL-6 release into EtOH-naïve CTRL medium. 
Both compounds reduced EtOH-induced increases in IL-6 release levels below that 
observed in CTRL and compound-treated CTRL media. A kit provided (R & D Systems) 
IL-6 positive control was used. * = p < 0.05 vs CTRL or corresponding compound 












 3.5. Discussion 
 Screens for natural product analogs from our lab identified a novel isoflavonoid 
analog, compound 9b, which completely attenuated 48 h EtOH-induced cytotoxicity in 
hippocampal slice cultures (Study 1). Several isoflavonoids (e.g., puerarin, daidzin, DZ) 
have been shown to reduce EtOH intake in vivo (Lin & Li, 1998; Benlhabib et al., 2004) 
and in humans (Lukas et al., 2005; 2013; Penetar et al., 2012; 2015). Although the precise 
mechanism by which isoflavonoids attenuate consumption is not yet known, recent 
studies suggests that DZ may inhibit pro-inflammatory neuroimmune signaling through 
action at TLR4 (Morimoto et al., 2009; Subedi et al., 2017). HMGB1-TLR4 signaling 
and downstream activation of neuroimmune mediators has been shown to contribute to 
EtOH-induced excitotoxicity, neurodegeneration, and behavioral deficits (Blanco et al., 
2005; Fernandez-Lizarbe et al., 2009; Alfonso-Loeches et al., 2010; Pascual et al., 2011; 
Liu et al., 2011). Thus, the present studies sought to evaluate the cytoprotective, and 
potentially anti-inflammatory, properties of compound 9b in the same in vitro model of 
EtOH-induced cytotoxicity, with the addition of a neuroimmune component. However, as 
9b was found to have its greatest cytoprotective effect against EtOH-induced cytotoxicity 
at 0.01 µM (the lowest concentration tested in Study 1; Figure 2.8), lower concentrations 
were evaluated to establish a dose-dependent response. Specifically, OHSC were co-
exposed to EtOH and 9b for 48 h, at which point cultures were assessed for PI uptake, a 
measure of cell death, and the release of inflammatory mediators (HMGB1, TNF-α, IL-6, 
IL-10) into the culture medium. In prior studies, including Study 1, we found that a 48 h 
EtOH exposure results in significant cytotoxicity (Wang et al., 2015; Shaaban et al, 
2017). While prior studies have demonstrated dose-dependent increases in HMGB1 
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 release and TNF-α mRNA following a 48 h exposure to EtOH (25-100mM) in rat HEC 
slice cultures (Coleman et al., 2017), the interactions between EtOH and these mediators 
in OHSC, as well as the impact of isoflavonoids such as 9b on these responses, is not yet 
known. Thus, as the effects of DZ have been evaluated in other models of AUD (Lin & 
Li, 1998; Benlhabib et al., 2004; Lukas et al., 2005; 2013; Penetar et al., 2012; 2015) and 
has known effects on neuroimmune signaling (Morimoto et al., 2009; Subedi et al., 
2017), it was used as a comparison compound to assess any potential value of observed 
effects of 9b in our model.  
 We have previously shown that compound 9b (0.01 µM ) completely attenuates 
EtOH-induced cytotoxicity at 48 h (Study 1). Therefore, in order to assess dose-
dependent responses, Study 2 aimed to characterize the cytoprotective effects of 9b at a 
lower concentration range (0.0001-0.01 µM). As the prototypical isoflavonoids daidzein 
and genistein have been shown to have dose dependent anti-apoptotic actions down to 
0.05 µM in a previous study (Adams et al., 2012), we expected 0.01 µM to remain the 
most cytoprotective concentration. We found that 9b dose-dependently inhibited PI-
uptake; and consistent with our hypothesis, the 0.01 µM co-exposure treatment was the 
most effective at attenuating EtOH-induced cytotoxicity (Figure 3.2). When compared 
with DZ (0.0001-0.01 µM), 9b was slightly less potent. Specifically, DZ was 
cytoprotective at the 0.0001 µM concentration, compared to 9b, which was only 
cytoprotective down to the 0.001 µM concentration (Figure 3.3). These data suggest that 




 In addition to further characterizing the cytoprotective effects of 9b, the current 
study aimed to assess its potential in reducing EtOH-induced release of pro-inflammatory 
mediators. Previous studies have shown that EtOH exposure upregulates the TL4R 
agonist HMGB1, which then leads to the activation of downstream signaling cascades 
and cytokine (e.g., TNF-α, IL-6) release (Crews et al., 2015). Additionally, inhibition of 
these cascades has been shown to afford neuroprotection (Blanco et al., 2005; Fernandez-
Lizarbe et al., 2009; Alfonso-Loeches et al., 2010; Pascual et al., 2011; Wu et al., 2015; 
Subedi et al., 2017). DZ and its metabolite, eqoul, have been shown to attenuate LPS-
induced cytokine release through action at the TLR4 (Morimoto et al., 2009; Subedi et 
al., 2017). Interestingly, 9b exhibited structural similarities to lobeline and σ-1R 
antagonists, compounds which have been shown to attenuate EtOH consumption (Bell et 
al., 2009; Farook et al., 2009; Sabino et al., 2009) and have inhibitory effects on pro-
inflammatory neuroimmune signaling (Hosur & Loring, 2010; Yao et al., 2010), and 
were unique from DZ. Thus, we hypothesized that co-exposure to 9b or DZ would inhibit 
EtOH-induced pro-inflammatory mediator release into medium during a 48 h EtOH 
exposure. Additionally, due to its unique structural properties, we hypothesized that 9b 
might have more anti-inflammatory potential than DZ. In the current study, DZ and 9b 
reduced EtOH-induced HMGB1 and IL-6 during EtOH exposure (Figure 3.4; 3.5), but 9b 
did not exhibit more anti-neuroinflammatory potential than DZ. Specifically, while 9b 
and DZ inhibited the upstream release of HMGB1 at similar potencies (Figure 3.4), DZ 
co-exposure had a larger effect (Cohen’s d= 27.0, 0.01 µM) than 9b (Cohen’s d= 7.5, 
0.01 µM) on IL-6 release into media during a 48 h EtOH exposure (Figure 3.5). Notably, 
isoflavonoids are phytoestrogens, and DZ is known to have a high affinity for estrogen 
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 receptors (Kostelac, Rechkemmer, & Briviba, 2003). Estradiol has been demonstrated to 
directly reduce NF-κB activity and cytokine production in macrophages in vitro 
(Deshpande, Khalili, Pergolizzi, Michael, & Chang, 1997), and estrogen treatment in 
male mice has been shown to decrease IL-6 secretion in a model of EtOH-administration 
and burn injury (Messingham, Heinrich, & Kovacs, 2001). Interestingly, this suggests 
effects on NF-κB which are independent of HMGB1-TLR4 (Deshpande et al., 1997). 
Thus, this potentiated effect of DZ on IL-6 release may reflect a greater affinity for 
estrogen receptor binding compared to compound 9b; in drug R & D, a lower affinity for 
estrogen receptors is desirable for pharmacotherapies expected to be administered to 
female populations (Dinsdale & Ward, 2010). However, future studies should evaluate 
the estrogen binding affinity of 9b, as everything discussed here is just speculation. 
Furthermore, while direct correlations cannot be conducted due to the pooling of media 
samples, observable disparities in the cytoprotective effects of 9b and DZ, compared to 
their inhibition of IL-6 release, suggests that 9b may be exerting its cytoprotective effects 
via additional mechanisms not tested in the current study. These findings support the 
potential use of isoflavonoids such as 9b and DZ to reduce pro-inflammatory 
neuroimmune signaling during EtOH exposure.  
However, the conclusions of the current study are limited, as only a few 
neuroimmune markers were measured. The original hypothesis stated that EtOH 
exposure would enhance pro-inflammatory cytokine release, which in turn would be 
inhibited by compounds that afforded cytoprotection. As such, we chose to focus on 
HMGB1 and TNF-α, as these markers have been well established in EtOH models in 
vitro (Crews et al., 2013; Coleman et al., 2017). However, while our hypothesis was 
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 supported by our HMGB1 findings, TNF-α levels were below the limits of detection in 
our culture media. Thus, we measured IL-6 as an alternative pro-inflammatory cytokine, 
due to its presence in serum in clinical AUD populations (Heberlein et al., 2014; Zago et 
al., 2016) and recent findings suggesting binge EtOH intake is dependent on IL-6 in vivo 
(Casachahua, 2016). As HMGB1 can also have anti-inflammatory action based on its 
redox state (Venereau et al., 2012), we also attempted to measure IL-10 (an anti-
inflammatory cytokine). However, similar to TNF-α, IL-10 levels were below the limits 
of detection in our culture medium. While TNF-α and IL-10 ELISAs have been 
performed by Lutz and colleagues (2015) using medium from OHSC, suggesting these 
mediators can be detected in culture medium, initial assays for these ELISAs lacked a 
positive control (R & D systems provided an IL-6 positive control with kit). Thus, an 
additional post-hoc study was conducted to assess the effect of LPS (10 ug/mL) on 
release of HMGB1, TNF-α, and IL-10 into control medium. Unfortunately, while LPS 
(10 ug/mL) did produce detectable levels of release in all assays, both the TNF-α and IL-
10 ELISAs presented with low standard signal, complicating the interpretation of their 
results. The low standard signal may have been due to the use of previously opened and 
re-sealed ELISA kits. Future studies should evaluate these, and additional, neuroimmune 
markers in order to further assess how neuroimmune signaling is affected by EtOH 
exposure and isoflavonoid treatment.  
In summary, compound 9b reduced EtOH-induced cytotoxicity and neuroimmune 
signaling during a 48 h exposure period. However, contrary to our hypothesis, 9b was not 
as potent as the comparison compound DZ. Future studies should continue to investigate 
the possible therapeutic role of neuroimmune signaling modulation during EtOH 
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 exposure, as well as the potential use of isoflavonoid compounds such as 9b and DZ for 

















 CHAPTER FOUR: General Discussion 
Approximately 14% of Americans currently meet criteria for AUD, and this 
statistic is only expected to rise (Grant et al., 2017).  While there are 4 medications 
approved by the FDA to treat AUD, disulfiram (Antabuse©), naltrexone (Revia©, 
Vivitrol©), and acamprosate (Campral©), they have high failure rates (Johnson, 2008; 
Moos and Moos, 2006; Heinz et al., 2009); however, among persons 12 and older 
needing treatment for AUD, there is a self-indicated desire for effective 
pharmacotherapy-based treatment options (SAMHSA, 2014). The lack of efficacy of 
these pharmacotherapies may be because they work at preventing future drug 
consumption by lowering its value to the user, and not by targeting the underlying 
neurological dysfunction induced by alcohol (Koob & Le Moal, 1997; Van Skike et al., 
2016). However, drug research and development is an expensive and high risk venture, 
costing an average of $2.6 billion per new drug brought to market in the United States 
(DiMasi et al., 2016). Natural product compounds could provide an advantage in drug R 
& D for neurodegenerative diseases, as they display complex chiral structures that may 
confer an enhanced fit to receptors and other target proteins (Mentel, Blankenfeldt, & 
Breinbauer, 2009). Initial screens of several natural product compounds identified 3 
compounds which attenuate 48 h EtOH (100mM)-induced cytotoxicity in a rodent OHSC 
(Wang et al., 2015; Shaaban et al., 2017; Zhang et al., 2017). However, during compound 
screening and optimization, analogs can be developed which have enhanced 
characteristics over their parental structures (Kerns & Di, 2003). Thus, the current studies 
aimed to assess the effects of natural product compound analogs on EtOH-induced 
cytotoxicity within our model. Additionally, as EtOH may exert its neurotoxicity via 
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 induction of pro-inflammatory neuroimmune signaling (Crews et al., 2015), we aimed to 
assess whether compound hits in our model inhibited pro-inflammatory neuroimmune 
mediators. In Study 1, 9 compound analogs were identified which protected against 48 h 
EtOH (100 mM)-induced cytotoxicity. In Study 2, we found that an isoflavonoid analog, 
9b, attenuated EtOH-induced cytotoxicity and release of pro-inflammatory mediators 
HMGB1 and IL-6 into culture media at 48 h. Additionally, as 9b is a novel analog, Study 
2 investigated the effects of the prototypical isoflavonoid, daidzein (DZ), for comparison. 
DZ was also found to significantly attenuate EtOH-induced cytotoxicity and release 
neuroimmune mediators at 48 h. However, DZ was more potent than compound 9b at 
attenuating EtOH-induced cytotoxicity and IL-6 release, exhibiting these effects at all 
concentrations tested. Isoflavonoids are known phytoestrogens, and estradiol can directly 
inhibit NF-κB activity and cytokine production (Deshpande et al., 1997; Messingham et 
al., 2001). These findings, while tentative, may suggest 9b has a lower affinity for the 
estrogen receptor than DZ, a property which is desirable when developing drugs to be 
administered to female populations (Dinsdale & Ward, 2010).  
While Study 1 identified 9 novel compound analogs which afford cytoprotection 
in our model (compounds 2a, 4a, 5a, 6, 7, 9b, 9d, 10, and 11), Study 2 only further 
evaluated a single compound (compound 9b) for inhibitory effects on EtOH-induced pro-
inflammatory mediators. Compounds 2a, 4a, and 5a are all analogs of compound 
structures isolated from Streptomyces sp. RM-14-6, an extremophile bacteria isolate from 
the underground Ruth Mullins coal mine (Shaaban et al., 2017). Compounds 2a and 4a 
were revealed to be structurally related to spoxamicin D, which previously demonstrated 
potent neuroprotective effects in our model (Shaaban et al., 2017), but was advanced to in 
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 vivo screening for EtOH self-administration in alcohol preferring (P) rats and had no 
effect on drinking behavior (unpublished data). While this does not mean that these 
compound analogs would not be effective in vivo, it did reduce their interest when 
compared to the isoflavonoid analogs (9b and 9d), as isoflavonoids have proven effective 
at reducing EtOH intake in both rodents (Lin & Li, 1998; Benlhabib et al., 2004) and 
humans (Lukas et al., 2005; 2013; Penetar et al., 2012; 2015). Isoflavonoids have also 
been shown to reduce the severity of EWD, suggesting they may be useful administered 
at various phases of dependence (Overstreet et al., 2003; Benlhabib et al., 2004; Lutz et 
al., 2015a). Compound 5a was revealed to be an analog of oxachelin, which previously 
demonstrated no cytoprotective effects in our model (Shaaban et al., 2017; Zhang et al., 
2017). A related compound, oxachelin C, was cytoprotective; however, it did not pass in 
silico BBB screens (Shaaban et al., 2017). While compound 5a did pass in silico screens, 
it is still a very large compound (Figure reference). In silico predictions are not perfect 
(Kelly, 2009), and doubts about 5a’s BBB permeability have been raised (personal 
communication, Dr. Yinan Zhang). Furthermore, the lack of knowledge surrounding 
several hit compound structures (6, 7, 10, and 11), restricted our ability to determine the 
value of their use.  
Notably, Study 1 was useful in providing information on whether compounds 
were cytoprotective against the effects of EtOH, but it was not useful in providing 
information on the mechanism(s) by which those compounds exerted their 
cytoprotection. HMGB1-TLR4 signaling and downstream activation of neuroimmune 
mediators has been shown to contribute to EtOH-induced excitotoxicity, 
neurodegeneration, and behavioral deficits (Blanco et al., 2005; Fernandez-Lizarbe et al., 
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 2009; Alfonso-Loeches et al., 2010; Pascual et al., 2011; Liu et al., 2011). Therefore, 
Study 2 evaluated the effects of compound 9b, and a comparison compound DZ, on 
EtOH-induced pro-inflammatory neuroimmune mediators. Specifically, we chose to 
examine the effects of 9b on EtOH-induced changes in HMGB1, TNF-α, and IL-6 as 
these mediators have been well established in binge-EtOH models in vitro and in rodents 
(Crews et al., 2013; Casachahua, 2016; Coleman et al., 2017). We also examined the 
effects of EtOH on the release of the anti-inflammatory cytokine IL-10, as HMGB1 can 
have anti-inflammatory effects dependent on its redox state (Venereau et al., 2012). 
While the literature primarily discusses an increase in IL-10 release in the context of 
acute EtOH exposure, Marshall, McKnight, Blose, Lysle, and Thiele (2017) have shown 
that IL-10 is decreased in the amygdala of male C57BL/6J mice following a 4-day binge 
EtOH exposure. Similarly, Peng and colleagues (2017) found both M1 (pro-
inflammatory) and M2 (anti-inflammatory)-like microglia expression in the rat 
hippocampus and entorhinal cortex following a similar 4 day binge, suggesting 
overlapping patterns of neuroimmune signaling may occur. As mentioned previously, we 
demonstrated inhibitory effects of both 9b and DZ against EtOH-induced HMGB1 and 
IL-6 release into culture media at 48 h. However, we could not assess these compounds’ 
effects on TNF-α or IL-10 as we did not find detectable levels of these cytokines released 
into media following a 48 h EtOH exposure. Unlike our measure of cytotoxicity 
(Saunders, 2016), prior to the current studies, a timeline characterizing the release of 
these mediators in response to EtOH in our model was not established. One important 
hindrance this lack of timeline presents is that we are prevented from making any causal 
interpretations between EtOH-induced neuroimmune signaling and cytotoxicity in 
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 OHSC.  A review by Wang, Yang, and Tracey (2004) found that secretion of TNF-α in 
response to systematic inflammation occurs on a separate timeline from HMGB1 release. 
Specifically, HMGB1 release correlates with the onset of cell death, but is delayed in 
response to early TNF-α release. Notably, TNF-α release was observed to be bi-phasic, 
with an additional peak in release observed 4-10 h following HMGB1 release (Wang et 
al., 2004). Thus, it is possible that we are simply missing the time point for TNF-α and 
IL-10 release with a single 48 h measurement within our model.  
Alternatively, while TNF-α release has been shown in several in vitro and rodent 
models, Zahr, Luong, Sullivan, and Pfefferbaum (2010) did not find this cytokine to be 
upregulated in the liver or brain (anterior cerebellar vermis, cingulate cortex, frontal 
cortex, hippocampus, hypothalamus, striatum) of male Wister rats following a 4-day 
binge EtOH exposure. Furthermore, human studies have found that measures of alcohol 
consumption, craving, and EWD severity are more strongly associated with serum levels 
of IL-6 than TNF-α (Heberlein et al., 2014). More recent studies have failed to find any 
relationship with TNF-α, associating only increased IL-6 and decreased IL-10 serum 
levels with AUD measures (Zago et al., 2016). These studies call into question the 
importance of TNF-α, compared to IL-6, as a target for the screening of novel 
pharmacotherapies for AUD.  
As previously discussed, the OHSC culture model was chosen as it has been 
validated in the study of EtOH-induced changes in the brain (Bulter et al., 2013; 
Reynolds et al., 2015a; Reynolds et al., 2016) and preserves neuron-glia interactions 
which are important in the development of this neuropathology (for a review, see Crews 
et al., 2015). Furthermore, the hippocampus also lends clinical relevancy, as this region 
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 has been implicated in the development of many of the neurobehavioral deficits observed 
in alcoholics (Sullivan, Rosenbloom, & Pfefferbaum, 2000; Chanraud, et al., 2007; Pitel 
et al., 2007; Makris et al., 2008; Müller, 2013; Ozoy et al., 2013; Kutlu & Gould, 2016). 
Notably, OHSC used in these studies were taken from rat pups at post-natal (PND) day 8, 
and although the effects of EtOH were not analyzed until 7 DIV (or PND day 15), this 
time period still involves overlap with the third trimester “brain growth spurt” equivalent 
period in rats (PND 1-10) (West, 1987). Additionally, similar OHSC preparations have 
been used to study the effects of EtOH exposures and neuroimmune signaling on fetal 
brain development (Barron, Mulholland, Littleton, & Prendergast, 2008; Moon et al., 
2014). However, OHSCs taken from postnatal rat pups do maintain structural and 
functional integrity over time (Gutierrez & Heinemann, 1999), and observations of 
OHSC taken from PND 6 pups and aged for 24 days revealed a similar distribution of 
hippocampal glutamate receptors to PND 30 rat brain in situ (Martens & Wree, 2001). 
This suggests that effects observed in cultures taken from postnatal pups may hold 
implications for the adolescent or adult rat brain. Moreover, our lab has reliably 
translated several findings from OHSC to adult rat in vivo studies (Reynolds et al., 2015c; 
Reynolds et al., 2016).  In kind with the current study, Tajuddin, Kim, and Collins (2018) 
revealed that a 4-day 100 mM EtOH exposures results in neurodegeneration through 
induction of HMGB1-TLR4 signaling in adult-age HEC cultures. Thus, while the current 
studies provide support that changes neuroimmune signaling may contribute to EtOH-
induced toxicity in the brain, the implication that the therapeutic targets identified in 
these studies may be relevant to EtOH-induced neurotoxicity during development should 
also be considered.  
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  The current studies are the first to our knowledge to demonstrate inhibitory 
effects of isoflavonoids and isoflavonoid analogs against binge-like EtOH-induced 
cytotoxicity and pro-inflammatory neuroimmune signaling. The main findings from these 
studies are that structural modifications to natural product compounds (e.g., via 
glycosylation, fluorination, addition of piperidine) can have a positive effect on BBB 
permeability and/or cytoprotection. Furthermore, isoflavonoids may exert their 
cytoprotective effects via modulation of pro-inflammatory neuroimmune signaling. 
Future research should continue to explore the precise mechanism by which the novel 
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